,level_0,Unnamed: 0,index,Unnamed: 0.1,text,drug1,drug2,ddi,type,label,smile1,smile2,pos1,pos2
0,54,54,55,55,"These drugs include the DRUG1 and other DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",thiazides,phenytoin,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,4,14
1,112,112,113,113,"No significant interactions with DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, oral DRUGOTHER, DRUGOTHER, or DRUGOTHER have been observed.",hydrochlorothiazide,hydralazine,False,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,C1=CC=C2C(=C1)C=NN=C2NN,5,6
2,129,129,130,130,DRUGOTHER modifies DRUG1 metabolism with increased serum levels of DRUG1.,phenytoin,phenytoin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,2,-1
3,144,144,146,146,"DRUG1: If DRUGOTHER is given concurrently with DRUG2, the protein binding of DRUG2 may be reduced.",Phenytoin,phenytoin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,0,7
4,145,145,147,147,"DRUG1: If DRUGOTHER is given concurrently with DRUG2, the protein binding of DRUG2 may be reduced.",Phenytoin,phenytoin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,0,7
5,146,146,148,148,"DRUGOTHER: If DRUGOTHER is given concurrently with DRUG1, the protein binding of DRUG1 may be reduced.",phenytoin,phenytoin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,7,-1
6,198,198,200,200,The effects of DRUGOTHER are antagonized by DRUG1 such as DRUG2 and DRUGOTHER.,methylxanthines,caffeine,False,Neg,0,O=C1NC2=C(NC=N2)C(=O)N1,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,7,10
7,199,199,201,201,The effects of DRUGOTHER are antagonized by DRUG1 such as DRUGOTHER and DRUG2.,methylxanthines,theophylline,False,Neg,0,O=C1NC2=C(NC=N2)C(=O)N1,CN1C2=C(C(=O)N(C1=O)C)NC=N2,7,12
8,200,200,202,202,The effects of DRUGOTHER are antagonized by DRUGOTHER such as DRUG1 and DRUG2.,caffeine,theophylline,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CN1C2=C(C(=O)N(C1=O)C)NC=N2,10,12
9,245,245,247,247,DRUG1: The pharmacokinetics of DRUG2 (DRUGOTHER 5.8 mg/kg infused over 20 minutes) were unchanged following a single oral dose of DRUGOTHER (400 mg) in 6 healthy subjects.,Theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,0,4
10,328,328,332,332,"Co-administration of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER did not result in clinically significant increases in DRUGOTHER exposure.",furosemide,hydrochlorothiazide,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,5,8
11,430,430,434,434,"DRUG1: When DRUGOTHER was co-administered with DRUG2, the AUC and Cmax of DRUG2 were reduced by about 30% and 50%, respectively.",Furosemide,furosemide,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,0,6
12,431,431,435,435,"DRUG1: When DRUGOTHER was co-administered with DRUG2, the AUC and Cmax of DRUG2 were reduced by about 30% and 50%, respectively.",Furosemide,furosemide,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,0,6
13,434,434,438,438,"DRUGOTHER: When DRUGOTHER was co-administered with DRUG1, the AUC and Cmax of DRUG1 were reduced by about 30% and 50%, respectively.",furosemide,furosemide,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,6,-1
14,907,907,928,928,"In addition to the interactions noted above, chronic (  2 weeks) oral DRUGOTHER administration impairs metabolism of DRUG1, DRUG2, and DRUGOTHER.",phenytoin,dextromethorphan,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C,18,19
15,1041,1041,1065,1065,"For comprehensive information concerning laboratory test alterations associated with DRUG1, physicians should refer to the complete prescribing information for DRUG2 (DRUG1).",ritonavir,NORVIR,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,9,19
16,1042,1042,1066,1066,"For comprehensive information concerning laboratory test alterations associated with DRUG1, physicians should refer to the complete prescribing information for DRUGOTHER (DRUG1).",ritonavir,ritonavir,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,9,-1
17,1043,1043,1067,1067,"For comprehensive information concerning laboratory test alterations associated with DRUG2, physicians should refer to the complete prescribing information for DRUG1 (DRUG2).",NORVIR,ritonavir,False,Neg,0,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,19,9
18,1325,1325,1361,1361,"Drugs that have been reported to diminish oral DRUGOTHER response, ie, decreased prothrom-bin time response, in man significantly include: DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;diet high in DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUG2;oral DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER;DRUGOTHER under-dosage.",haloperidol,meprobamate,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,22,22
19,2265,2265,2301,2301,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUG2;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",pentoxifylline,phenytoin,False,Neg,0,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,20,20
20,2273,2273,2309,2309,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;DRUGOTHER;DRUGOTHER;DRUGOTHER;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG2, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",pentoxifylline,sulfonamides,False,Neg,0,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,20,22
21,2315,2315,2351,2351,"Drugs that reportedly may increase oral DRUGOTHER response, ie, increased prothrombin response, in man include:DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;dietary deficiencies;DRUGOTHER;DRUGOTHER;drugs affecting blood elements;DRUGOTHER;DRUGOTHER;DRUGOTHER;hepatotoxic drugs;DRUGOTHER;DRUGOTHER;DRUGOTHER;inhalation DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUG1;prolonged hot weather;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER*;DRUGOTHER;DRUGOTHER;DRUG2, long acting;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER;DRUGOTHER/DRUGOTHER;unreliable prothrombin time determinations;DRUGOTHER overdosage.",phenytoin,sulfonamides,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,20,22
22,2404,2404,2440,2440,"Because oral DRUGOTHER may interfere with the hepatic metabolism of DRUG1, toxic levels of the DRUGOTHER may occur when an oral DRUGOTHER and DRUG1 are administered concurrently.",phenytoin,phenytoin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,10,-1
23,2629,2629,2672,2672,"Consequently, concomitant administration of DRUGOTHER with strong CYP3A4 inhibitors (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) should be approached with caution.",nefazodone,ritonavir,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,12,15
24,2709,2709,2752,2752,"Concomitant treatment with DRUG1 (DRUGOTHER, DRUG2), DRUGOTHER, or DRUGOTHER may potentiate any hypokalemic effect of DRUGOTHER.",methylxanthines,theophylline,False,Neg,0,O=C1NC2=C(NC=N2)C(=O)N1,CN1C2=C(C(=O)N(C1=O)C)NC=N2,3,5
25,2730,2730,2773,2773,"The concurrent use of intravenously or orally administered DRUG1 (e.g., DRUGOTHER, DRUG2) by patients receiving DRUGOTHER has not been completely evaluated.",methylxanthines,theophylline,False,Neg,0,O=C1NC2=C(NC=N2)C(=O)N1,CN1C2=C(C(=O)N(C1=O)C)NC=N2,8,11
26,2851,2851,2894,2894,"In in vivo studies, 10- to 30-mg/day doses of DRUGOTHER had no significant effect on metabolism by CYP2D6 (DRUG1), CYP2C9 (DRUGOTHER), CYP2C19 (DRUGOTHER, DRUGOTHER), and CYP3A4 (DRUG1) substrates.",dextromethorphan,dextromethorphan,False,Neg,0,[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C,[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C,18,-1
27,2892,2892,2935,2935,DRUG1: Serum DRUG2 levels may be increased by DRUGOTHER.,Phenytoin,phenytoin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,0,2
28,2978,2978,3024,3024,"The extent of plasma protein binding of DRUGOTHER in human plasma is not affected by the presence of therapeutic concentrations of DRUG1 (15 mcg/ mL), nor is the binding of DRUG1 affected by the presence of DRUGOTHER.",phenytoin,phenytoin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,21,-1
29,3266,3266,3327,3327,"Other No clinically important pharmacokinetic interactions occurred when DRUGOTHER was administered concomitantly with DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER.",hydrochlorothiazide,furosemide,False,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,13,15
30,3324,3324,3392,3392,"DRUGOTHER may interact with DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), local DRUGOTHER (e.g., DRUGOTHER and DRUGOTHER), DRUGOTHER (DRUGOTHER)-containing preparations (e.g., sunscreens and some DRUGOTHER), DRUGOTHER (e.g., DRUG1), DRUG2 (sulfa medicines), DRUGOTHER (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).",Pronestyl,sulfonamides,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,26,27
31,3352,3352,3420,3420,"In general, these are drugs that have one or more pharmacologic activities similar to DRUG1, including DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER and DRUG2.",bepridil hydrochloride,tricyclic anti-depressants,False,Neg,0,CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,14,24
32,3359,3359,3427,3427,DRUGOTHER and DRUG1 could exaggerate the prolongation of the QT interval observed with DRUG2.,tricyclic anti-depressants,bepridil hydrochloride,True,effect,2,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1,2,13
33,3681,3681,3779,3779,"If treatment with inhibitors of CYP3A4 activity (such as DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, etc.) is indicated, reduction of the DRUGOTHER dose should be considered.",ritonavir,saquinavir,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,11,13
34,3720,3720,3818,3818,"DRUGOTHER), DRUGOTHER (e.g. DRUGOTHER), and DRUGOTHER (e.g. DRUG1, DRUGOTHER and DRUG2) should have their dose of DRUGOTHER or DRUGOTHER adjusted.",ritonavir,saquinavir,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,7,10
35,3721,3721,3819,3819,"DRUGOTHER), DRUGOTHER (e.g. DRUGOTHER), and DRUGOTHER (e.g. DRUG1, DRUGOTHER and DRUGOTHER) should have their dose of DRUG2 or DRUGOTHER adjusted.",ritonavir,SUBUTEX,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4,7,16
36,3726,3726,3824,3824,"DRUGOTHER), DRUGOTHER (e.g. DRUGOTHER), and DRUGOTHER (e.g. DRUGOTHER, DRUGOTHER and DRUG1) should have their dose of DRUG2 or DRUGOTHER adjusted.",saquinavir,SUBUTEX,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4,10,16
37,3731,3731,3829,3829,"In many of these cases, DRUG1 was misused by self-injection of crushed DRUG2 tablets.",buprenorphine,SUBUTEX,False,Neg,0,C[C@]([C@H]1C[C@@]23CC[C@@]1([C@H]4[C@@]25CCN([C@@H]3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)(C(C)(C)C)O,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4,5,12
38,3751,3751,3849,3849,"While not systematically studied, certain drugs may induce the metabolism of DRUG1 (e.g., DRUGOTHER, DRUGOTHER, DRUG2).",bupropion,phenytoin,True,mechanism,4,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,11,15
39,3755,3755,3853,3853,"Although DRUG1 is not metabolized by this isoenzyme, DRUG1 and hydroxyDRUG1 are inhibitors of the CYP2D6 isoenzyme in vitro.",bupropion,bupropion,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,1,-1
40,3768,3768,3866,3866,"Therefore, co-administration of DRUG1 with drugs that are metabolized by CYP2D6 isoenzyme including certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (e.g., DRUG2, DRUGOTHER, DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), and DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,haloperidol,True,advise,1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,3,24
41,3770,3770,3868,3868,"Therefore, co-administration of DRUG1 with drugs that are metabolized by CYP2D6 isoenzyme including certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUG2), DRUGOTHER (e.g., DRUGOTHER), and DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,thioridazine,True,advise,1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,3,26
42,3838,3838,3936,3936,"Therefore, co-administration of DRUGOTHER with drugs that are metabolized by CYP2D6 isoenzyme including certain DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (e.g., DRUG1, DRUGOTHER, DRUG2), DRUGOTHER (e.g., DRUGOTHER), and DRUGOTHER (e.g., DRUGOTHER, DRUGOTHER), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",haloperidol,thioridazine,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,24,26
43,3895,3895,3993,3993,"In a study in normal volunteers, concomitant administration of DRUGOTHER and DRUG1 resulted in increased serum DRUG1 concentrations.",haloperidol,haloperidol,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,11,-1
44,3926,3926,4024,4024,"Since the pharmacokinetics of DRUGOTHER were studied in patients treated with DRUG1, the clearance of DRUGOTHER at the recommended dose may be lower and exposure (AUC) higher in patients not treated with DRUG1.",phenytoin,phenytoin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,11,-1
45,4014,4014,4112,4112,"DRUGOTHER, DRUGOTHER and DRUG1 may enhance the effects of: other DRUGOTHERs, DRUGOTHER, general DRUGOTHER, DRUGOTHER such as DRUGOTHER, DRUGOTHER, or other DRUG2, causing increased CNS depression.",caffeine,CNS depressants,True,effect,2,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,3,21
46,4065,4065,4164,4164,The safety of using DRUGOTHER and DRUG1 (DRUG2) Nasal Spray during the same episode of migraine has not been established.,IMITREX,sumatriptan,False,Neg,0,CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,6,7
47,4077,4077,4178,4178,"DRUG1 should not be administered concurrently with D2-antagonists, such as DRUGOTHER, DRUGOTHER, DRUG2, or DRUGOTHER.",DOSTINEX,thioxanthines,True,advise,1,[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC,O=C1NC2=C(NC=N2)C(=O)N1,0,12
48,4082,4082,4183,4183,"Based on adult data, lower doses of DRUG1 may be needed following coadministration of drugs which are reported to decrease DRUG1 elimination (e.g., DRUGOTHER and DRUGOTHER) and higher DRUG1 doses may be needed following coadministration of drugs that increase DRUG1 elimination (e.g., DRUGOTHER and DRUGOTHER).",caffeine,caffeine,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,7,-1
49,4085,4085,4186,4186,"Based on adult data, lower doses of DRUG1 may be needed following coadministration of drugs which are reported to decrease DRUG1 elimination (e.g., DRUGOTHER and DRUGOTHER) and higher DRUG1 doses may be needed following coadministration of drugs that increase DRUG1 elimination (e.g., DRUGOTHER and DRUGOTHER).",caffeine,caffeine,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,7,-1
50,4086,4086,4187,4187,"Based on adult data, lower doses of DRUG1 may be needed following coadministration of drugs which are reported to decrease DRUG1 elimination (e.g., DRUGOTHER and DRUGOTHER) and higher DRUG1 doses may be needed following coadministration of drugs that increase DRUG1 elimination (e.g., DRUGOTHER and DRUGOTHER).",caffeine,caffeine,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,7,-1
51,4088,4088,4189,4189,"Based on adult data, lower doses of DRUG1 may be needed following coadministration of drugs which are reported to decrease DRUG1 elimination (e.g., DRUGOTHER and DRUGOTHER) and higher DRUG1 doses may be needed following coadministration of drugs that increase DRUG1 elimination (e.g., DRUGOTHER and DRUG2).",caffeine,phenytoin,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,7,44
52,4091,4091,4192,4192,"Based on adult data, lower doses of DRUG1 may be needed following coadministration of drugs which are reported to decrease DRUG1 elimination (e.g., DRUGOTHER and DRUGOTHER) and higher DRUG1 doses may be needed following coadministration of drugs that increase DRUG1 elimination (e.g., DRUGOTHER and DRUGOTHER).",caffeine,caffeine,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,7,-1
53,4092,4092,4193,4193,"Based on adult data, lower doses of DRUG1 may be needed following coadministration of drugs which are reported to decrease DRUG1 elimination (e.g., DRUGOTHER and DRUGOTHER) and higher DRUG1 doses may be needed following coadministration of drugs that increase DRUG1 elimination (e.g., DRUGOTHER and DRUGOTHER).",caffeine,caffeine,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,7,-1
54,4094,4094,4195,4195,"Based on adult data, lower doses of DRUG1 may be needed following coadministration of drugs which are reported to decrease DRUG1 elimination (e.g., DRUGOTHER and DRUGOTHER) and higher DRUG1 doses may be needed following coadministration of drugs that increase DRUG1 elimination (e.g., DRUGOTHER and DRUG2).",caffeine,phenytoin,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,7,44
55,4104,4104,4205,4205,"Based on adult data, lower doses of DRUG1 may be needed following coadministration of drugs which are reported to decrease DRUG1 elimination (e.g., DRUGOTHER and DRUGOTHER) and higher DRUG1 doses may be needed following coadministration of drugs that increase DRUG1 elimination (e.g., DRUGOTHER and DRUGOTHER).",caffeine,caffeine,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,7,-1
56,4106,4106,4207,4207,"Based on adult data, lower doses of DRUG1 may be needed following coadministration of drugs which are reported to decrease DRUG1 elimination (e.g., DRUGOTHER and DRUGOTHER) and higher DRUG1 doses may be needed following coadministration of drugs that increase DRUG1 elimination (e.g., DRUGOTHER and DRUG2).",caffeine,phenytoin,True,advise,1,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,7,44
57,4108,4108,4209,4209,"Based on adult data, lower doses of DRUG1 may be needed following coadministration of drugs which are reported to decrease DRUG1 elimination (e.g., DRUGOTHER and DRUGOTHER) and higher DRUG1 doses may be needed following coadministration of drugs that increase DRUG1 elimination (e.g., DRUGOTHER and DRUG2).",caffeine,phenytoin,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,7,44
58,4111,4111,4212,4212,Interconversion between DRUG1 and DRUG2 has been reported in preterm neonates.,caffeine,theophylline,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CN1C2=C(C(=O)N(C1=O)C)NC=N2,2,4
59,4123,4123,4224,4224,"DRUG1/DRUGOTHER: The coadministration of DRUG2 or DRUGOTHER will not affect plasma concentrations of DRUGOTHER, but may reduce endogenous plasma levels of DRUGOTHER/ergoDRUGOTHER by accelerating metabolism.",Phenytoin,phenytoin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,0,4
60,4137,4137,4238,4238,DRUG1: DRUG1 are known to induce hypercalcemia by the reduction of calcium excretion in urine.,Thiazides,Thiazides,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,0,-1
61,4158,4158,4259,4259,"DRUG1/DRUGOTHER: The coadministration of DRUG2 or DRUGOTHER will not affect plasma concentrations of DRUGOTHER, but may reduce endogenous plasma levels of DRUGOTHER/ergoDRUGOTHER by accelerating metabolism.",Phenytoin,phenytoin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,0,4
62,4172,4172,4273,4273,DRUG1: DRUG1 are known to induce hypercalcemia by the reduction of DRUGOTHER excretion in urine.,Thiazides,Thiazides,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,0,-1
63,4243,4243,4348,4348,"The possibility of hypotensive effects with DRUG1 can be minimized by either discontinuing the DRUGOTHER or increasing the salt intake approximately one week prior to initiation of treatment with DRUG1 (DRUG1 tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg).",captopril,captopril,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,6,-1
64,4244,4244,4349,4349,"The possibility of hypotensive effects with DRUG1 can be minimized by either discontinuing the DRUGOTHER or increasing the salt intake approximately one week prior to initiation of treatment with DRUG1 (DRUG1 tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg).",captopril,captopril,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,6,-1
65,4247,4247,4352,4352,"The possibility of hypotensive effects with DRUG1 can be minimized by either discontinuing the DRUGOTHER or increasing the salt intake approximately one week prior to initiation of treatment with DRUG1 (DRUG1 tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg).",captopril,captopril,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,6,-1
66,4261,4261,4366,4366,DRUGOTHER: DRUG1 administered concurrently with DRUG2 does not alter the pharmacokinetics of DRUG2 in renally impaired hypertensive patients.,Furosemide,captopril,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,1,5
67,4262,4262,4367,4367,DRUGOTHER: DRUG1 administered concurrently with DRUG2 does not alter the pharmacokinetics of DRUG2 in renally impaired hypertensive patients.,Furosemide,captopril,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,1,5
68,4263,4263,4368,4368,DRUGOTHER: DRUGOTHER administered concurrently with DRUG1 does not alter the pharmacokinetics of DRUG1 in renally impaired hypertensive patients.,captopril,captopril,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,5,-1
69,4601,4601,4706,4706,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of DRUGOTHER are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1(2), DRUGOTHER, DRUGOTHER, and DRUG2 Thus, if a patient has been titrated to a stable dosage on DRUGOTHER, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for DRUGOTHER may be necessary.",Phenytoin,theophylline,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CN1C2=C(C(=O)N(C1=O)C)NC=N2,26,30
70,4790,4790,4895,4895,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",bupropion,doxycycline,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,30,41
71,4791,4791,4896,4896,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",bupropion,ethosuximide,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCC1(C)CC(=O)NC1=O,30,42
72,4795,4795,4900,4900,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",bupropion,haloperidol,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,30,46
73,4807,4807,4912,4912,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUG2(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",bupropion,Phenytoin,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,30,59
74,4811,4811,4916,4916,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",bupropion,theophylline,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,30,64
75,4812,4812,4917,4917,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",bupropion,topiramate,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,30,65
76,4818,4818,4923,4923,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUG2, and DRUGOTHER.",bupropion,ziprasidone,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,30,72
77,5126,5126,5231,5231,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",doxycycline,ethosuximide,False,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CCC1(C)CC(=O)NC1=O,41,42
78,5130,5130,5235,5235,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",doxycycline,haloperidol,False,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,41,46
79,5142,5142,5247,5247,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUG2(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",doxycycline,Phenytoin,False,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,41,59
80,5146,5146,5251,5251,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",doxycycline,theophylline,False,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,41,64
81,5147,5147,5252,5252,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",doxycycline,topiramate,False,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,41,65
82,5153,5153,5258,5258,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUG2, and DRUGOTHER.",doxycycline,ziprasidone,False,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,41,72
83,5158,5158,5263,5263,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",ethosuximide,haloperidol,False,Neg,0,CCC1(C)CC(=O)NC1=O,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,42,46
84,5170,5170,5275,5275,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUG2(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",ethosuximide,Phenytoin,False,Neg,0,CCC1(C)CC(=O)NC1=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,42,59
85,5174,5174,5279,5279,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",ethosuximide,theophylline,False,Neg,0,CCC1(C)CC(=O)NC1=O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,42,64
86,5175,5175,5280,5280,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",ethosuximide,topiramate,False,Neg,0,CCC1(C)CC(=O)NC1=O,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,42,65
87,5181,5181,5286,5286,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUG2, and DRUGOTHER.",ethosuximide,ziprasidone,False,Neg,0,CCC1(C)CC(=O)NC1=O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,42,72
88,5272,5272,5377,5377,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUG2(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",haloperidol,Phenytoin,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,46,59
89,5276,5276,5381,5381,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",haloperidol,theophylline,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,CN1C2=C(C(=O)N(C1=O)C)NC=N2,46,64
90,5277,5277,5382,5382,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",haloperidol,topiramate,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,46,65
91,5283,5283,5388,5388,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUG2, and DRUGOTHER.",haloperidol,ziprasidone,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,46,72
92,5486,5486,5591,5591,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUG1(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",Phenytoin,theophylline,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CN1C2=C(C(=O)N(C1=O)C)NC=N2,59,64
93,5487,5487,5592,5592,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUG1(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",Phenytoin,topiramate,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,59,65
94,5493,5493,5598,5598,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUG1(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUG2, and DRUGOTHER.",Phenytoin,ziprasidone,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,59,72
95,5525,5525,5630,5630,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUGOTHER, and DRUGOTHER.",theophylline,topiramate,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,64,65
96,5531,5531,5636,5636,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUG2, and DRUGOTHER.",theophylline,ziprasidone,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,64,72
97,5538,5538,5643,5643,"Agents that have been found, or are expected to have decreased plasma levels in the presence of DRUGOTHER due to induction of CYP enzymes are the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER(3), DRUGOTHER, DRUGOTHER(4), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER(5) , DRUG2, and DRUGOTHER.",topiramate,ziprasidone,False,Neg,0,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,65,72
98,5711,5711,5829,5829,"DRUG1 reduced the blood AUC0-12 of DRUGOTHER by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when DRUGOTHER (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of DRUG1 70 mg daily, as compared to results from a control period in which DRUGOTHER was administered alone.",CANCIDAS,CANCIDAS,False,Neg,0,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN,0,-1
99,5738,5738,5856,5856,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, or DRUGOTHER) with DRUG2 may result in clinically meaningful reductions in DRUGOTHER concentrations.",phenytoin,CANCIDAS,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN,21,26
100,5739,5739,5857,5857,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, or DRUGOTHER) with DRUGOTHER may result in clinically meaningful reductions in DRUG2 concentrations.",phenytoin,caspofungin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN,21,34
101,5745,5745,5863,5863,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER) with DRUG1 may result in clinically meaningful reductions in DRUG2 concentrations.",CANCIDAS,caspofungin,False,Neg,0,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN,26,34
102,5748,5748,5866,5866,"When DRUG1 is co-administered with inducers of drug clearance, such as DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER, use of a daily dose of 70 mg of DRUG1 should be considered",CANCIDAS,phenytoin,True,advise,1,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,1,13
103,5751,5751,5869,5869,"When DRUG1 is co-administered with inducers of drug clearance, such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER, use of a daily dose of 70 mg of DRUG1 should be considered",CANCIDAS,CANCIDAS,False,Neg,0,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN,1,-1
104,5763,5763,5881,5881,"When DRUG2 is co-administered with inducers of drug clearance, such as DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, or DRUGOTHER, use of a daily dose of 70 mg of DRUG2 should be considered",phenytoin,CANCIDAS,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN,13,1
105,5861,5861,5982,5982,"DRUG1: Clinical studies, as well as post marketing observations, have shown that DRUGOTHER can reduce the natriuretic effect of DRUG2 and DRUGOTHER in some patients.",Furosemide,furosemide,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,0,19
106,5862,5862,5983,5983,"DRUG1: Clinical studies, as well as post marketing observations, have shown that DRUGOTHER can reduce the natriuretic effect of DRUGOTHER and DRUG2 in some patients.",Furosemide,thiazides,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,0,21
107,5863,5863,5984,5984,"DRUGOTHER: Clinical studies, as well as post marketing observations, have shown that DRUGOTHER can reduce the natriuretic effect of DRUG1 and DRUG2 in some patients.",furosemide,thiazides,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,19,21
108,6141,6141,6263,6263,"Example inhibitors include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",doxycycline,imatinib,False,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,7,9
109,6143,6143,6265,6265,"Example inhibitors include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",doxycycline,nefazodone,False,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,7,11
110,6156,6156,6278,6278,"Example inhibitors include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",imatinib,nefazodone,False,Neg,0,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,9,11
111,6189,6189,6311,6311,"Interactions may also occur with the following: DRUG1/DRUGOTHER, drugs used to treat an overactive thyroid, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER pain medication (e.g., DRUGOTHER), drugs used to aid sleep, drowsiness-causing DRUGOTHER (e.g., DRUGOTHER), any other drugs that may make you drowsy.",anti-depressants,guanethidine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,C1CCCN(CCC1)CCN=C(N)N,7,20
112,6192,6192,6314,6314,"Interactions may also occur with the following: DRUG1/DRUGOTHER, drugs used to treat an overactive thyroid, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER pain medication (e.g., DRUGOTHER), drugs used to aid sleep, drowsiness-causing DRUGOTHER (e.g., DRUGOTHER), any other drugs that may make you drowsy.",anti-depressants,cabergoline,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC,7,23
113,6222,6222,6344,6344,"Interactions may also occur with the following: DRUGOTHER/DRUGOTHER, drugs used to treat an overactive thyroid, DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER pain medication (e.g., DRUGOTHER), drugs used to aid sleep, drowsiness-causing DRUGOTHER (e.g., DRUGOTHER), any other drugs that may make you drowsy.",guanethidine,cabergoline,False,Neg,0,C1CCCN(CCC1)CCN=C(N)N,[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC,20,23
114,6282,6282,6404,6404,"These drugs include the DRUG1 and other DRUGOTHER, DRUGOTHER, DRUGOTHER, thyroid products, DRUGOTHER, oral DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",thiazides,phenytoin,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,4,15
115,6354,6354,6476,6476,"DRUG1/DRUGOTHER: The coadministration of DRUG2 or DRUGOTHER will not affect plasma concentrations of DRUGOTHER, but may reduce endogenous plasma levels of DRUGOTHER/ergoDRUGOTHER by accelerating metabolism.",Phenytoin,phenytoin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,0,4
116,6368,6368,6490,6490,DRUG1: DRUG1 are known to induce hypercalcemia by the reduction of calcium excretion in urine.,Thiazides,Thiazides,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,0,-1
117,6585,6585,6707,6707,"DRUGOTHER : DRUGOTHER is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER agents, DRUG2, and DRUGOTHER).",furosemide,theophylline,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CN1C2=C(C(=O)N(C1=O)C)NC=N2,28,31
118,6653,6653,6778,6778,"DRUGOTHER, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, certain DRUGOTHER, DRUGOTHER, DRUG2 and DRUGOTHER, thereby delaying elimination and increasing blood levels of these drugs.",phenytoin,theophylline,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CN1C2=C(C(=O)N(C1=O)C)NC=N2,20,28
119,6677,6677,6802,6802,"Interaction with DRUG1, DRUGOTHER and DRUG2 has also been reported to produce adverse clinical effects.",phenytoin,theophylline,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CN1C2=C(C(=O)N(C1=O)C)NC=N2,2,5
120,6681,6681,6806,6806,"However, a crossover study in healthy subjects receiving either DRUGOTHER 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of DRUG1 (DRUG2 , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state DRUG1 peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.",theophylline,Theo-Dur,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(NC=N2)C(=O)N(C)C1=O,25,26
121,6682,6682,6807,6807,"However, a crossover study in healthy subjects receiving either DRUGOTHER 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of DRUG1 (DRUGOTHER , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state DRUG1 peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.",theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,25,-1
122,6683,6683,6808,6808,"However, a crossover study in healthy subjects receiving either DRUGOTHER 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of DRUG2 (DRUG1 , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state DRUG2 peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.",Theo-Dur,theophylline,False,Neg,0,CN1C2=C(NC=N2)C(=O)N(C)C1=O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,26,25
123,6696,6696,6825,6825,There have been reports of DRUG1-related side-effects in patients on concomitant DRUG1-DRUGOTHER therapy.,theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,5,-1
124,6699,6699,6828,6828,"Therefore, monitoring of DRUG1 plasma levels should be considered and dosage of DRUG1 adjusted as required.",theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,3,-1
125,6755,6755,6889,6889,DRUG1: Altered serum levels of DRUG2 (increased and decreased) have been reported in patients receiving concomitant DRUGOTHER.,Phenytoin,phenytoin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,0,5
126,6765,6765,6899,6899,"DRUG1: As with some other DRUGOTHER, concurrent administration of DRUGOTHER with DRUG2 may lead to elevated serum concentrations of DRUG2 and prolongation of its elimination half-life.",Theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,0,11
127,6766,6766,6900,6900,"DRUG1: As with some other DRUGOTHER, concurrent administration of DRUGOTHER with DRUG2 may lead to elevated serum concentrations of DRUG2 and prolongation of its elimination half-life.",Theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,0,11
128,6769,6769,6903,6903,"DRUGOTHER: As with some other DRUGOTHER, concurrent administration of DRUGOTHER with DRUG1 may lead to elevated serum concentrations of DRUG1 and prolongation of its elimination half-life.",theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,11,-1
129,7323,7323,7476,7476,"The absorption of DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER was significantly decreased when given simultaneously with DRUGOTHER;",tetracycline,furosemide,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,3,4
130,7325,7325,7478,7478,"The absorption of DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER was significantly decreased when given simultaneously with DRUGOTHER;",tetracycline,hydrochlorothiazide,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,3,6
131,7328,7328,7481,7481,"The absorption of DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER was significantly decreased when given simultaneously with DRUGOTHER;",furosemide,hydrochlorothiazide,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,4,6
132,7428,7428,7601,7601,"The physician should be alert for possible combined drug actions, desirable or undesirable, involving DRUG1 even though DRUG1 has been used successfully concurrently with other drugs, including other cytotoxic drugs.",cyclophosphamide,cyclophosphamide,False,Neg,0,ClCCN(CCCl)P1(=O)NCCCO1,ClCCN(CCCl)P1(=O)NCCCO1,14,-1
133,7477,7477,7662,7662,Drugs that may increase DRUG1 plasma concentrations CYP3A4 Inhibitors: DRUG2 is a CYP3A4 substrate.,dasatinib,Dasatinib,False,Neg,0,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1,4,9
134,7482,7482,7667,7667,"Concomitant use of DRUG1 and drugs that inhibit CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increase exposure to DRUGOTHER and should be avoided.",SPRYCEL,ritonavir,True,mechanism,4,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,3,14
135,7485,7485,7670,7670,"Concomitant use of DRUG1 and drugs that inhibit CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increase exposure to DRUGOTHER and should be avoided.",SPRYCEL,nefazodone,True,mechanism,4,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,3,17
136,7487,7487,7672,7672,"Concomitant use of DRUG1 and drugs that inhibit CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) may increase exposure to DRUGOTHER and should be avoided.",SPRYCEL,saquinavir,True,mechanism,4,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,3,19
137,7488,7488,7673,7673,"Concomitant use of DRUG1 and drugs that inhibit CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2) may increase exposure to DRUGOTHER and should be avoided.",SPRYCEL,telithromycin,True,mechanism,4,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,3,20
138,7489,7489,7674,7674,"Concomitant use of DRUG1 and drugs that inhibit CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increase exposure to DRUG2 and should be avoided.",SPRYCEL,dasatinib,False,Neg,0,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,3,25
139,7530,7530,7715,7715,"Concomitant use of DRUGOTHER and drugs that inhibit CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increase exposure to DRUGOTHER and should be avoided.",ritonavir,nefazodone,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,14,17
140,7532,7532,7717,7717,"Concomitant use of DRUGOTHER and drugs that inhibit CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) may increase exposure to DRUGOTHER and should be avoided.",ritonavir,saquinavir,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,14,19
141,7533,7533,7718,7718,"Concomitant use of DRUGOTHER and drugs that inhibit CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2) may increase exposure to DRUGOTHER and should be avoided.",ritonavir,telithromycin,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,14,20
142,7534,7534,7719,7719,"Concomitant use of DRUGOTHER and drugs that inhibit CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increase exposure to DRUG2 and should be avoided.",ritonavir,dasatinib,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,14,25
143,7547,7547,7732,7732,"Concomitant use of DRUGOTHER and drugs that inhibit CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER) may increase exposure to DRUGOTHER and should be avoided.",nefazodone,saquinavir,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,17,19
144,7548,7548,7733,7733,"Concomitant use of DRUGOTHER and drugs that inhibit CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2) may increase exposure to DRUGOTHER and should be avoided.",nefazodone,telithromycin,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,17,20
145,7549,7549,7734,7734,"Concomitant use of DRUGOTHER and drugs that inhibit CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increase exposure to DRUG2 and should be avoided.",nefazodone,dasatinib,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,17,25
146,7553,7553,7738,7738,"Concomitant use of DRUGOTHER and drugs that inhibit CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2) may increase exposure to DRUGOTHER and should be avoided.",saquinavir,telithromycin,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,19,20
147,7554,7554,7739,7739,"Concomitant use of DRUGOTHER and drugs that inhibit CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER) may increase exposure to DRUG2 and should be avoided.",saquinavir,dasatinib,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,19,25
148,7555,7555,7740,7740,"Concomitant use of DRUGOTHER and drugs that inhibit CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1) may increase exposure to DRUG2 and should be avoided.",telithromycin,dasatinib,False,Neg,0,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,20,25
149,7556,7556,7741,7741,"In patients receiving treatment with DRUG1, close monitoring for toxicity and a DRUG1 dose reduction should be considered if systemic administration of a potent CYP3A4 inhibitor cannot be avoided.",SPRYCEL,SPRYCEL,False,Neg,0,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1,5,-1
150,7557,7557,7742,7742,Drugs that may decrease DRUG1 plasma concentrations CYP3A4 Inducers: Drugs that induce CYP3A4 activity may decrease DRUG1 plasma concentrations.,dasatinib,dasatinib,False,Neg,0,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,4,-1
151,7568,7568,7753,7753,"If DRUG1 must be administered with a CYP3A4 inducer, a dose increase in DRUG1 should be considered.",SPRYCEL,SPRYCEL,False,Neg,0,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1,1,-1
152,7570,7570,7755,7755,"DRUGOTHER/DRUG1: Long-term suppression of gastric acid secretion by DRUGOTHER or DRUG2 (eg, DRUGOTHER and DRUGOTHER) is likely to reduce DRUGOTHER exposure.",Proton Pump Inhibitors,proton pump inhibitors,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,0,10
153,7573,7573,7758,7758,"DRUGOTHER/DRUG1: Long-term suppression of gastric acid secretion by DRUGOTHER or DRUGOTHER (eg, DRUGOTHER and DRUGOTHER) is likely to reduce DRUG2 exposure.",Proton Pump Inhibitors,dasatinib,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,0,19
154,7576,7576,7761,7761,"DRUGOTHER/DRUGOTHER: Long-term suppression of gastric acid secretion by DRUGOTHER or DRUG1 (eg, DRUGOTHER and DRUGOTHER) is likely to reduce DRUG2 exposure.",proton pump inhibitors,dasatinib,True,effect,2,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,10,19
155,7580,7580,7765,7765,The concomitant use of DRUGOTHER or DRUG1 with DRUG2 is not recommended.,proton pump inhibitors,SPRYCEL,True,advise,1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1,6,8
156,7581,7581,7766,7766,The use of DRUGOTHER should be considered in place of DRUGOTHER or DRUG1 in patients receiving DRUG2 therapy.,proton pump inhibitors,SPRYCEL,True,advise,1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1,12,16
157,7582,7582,7767,7767,Drugs that may have their plasma concentration altered by DRUG1 CYP3A4 Substrates: DRUG2 is a time-dependent inhibitor of CYP3A4.,dasatinib,Dasatinib,False,Neg,0,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1,9,12
158,7640,7640,7825,7825,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, or DRUGOTHER (DRUGOTHER, dihydroDRUGOTHER) should be administered with caution in patients receiving DRUGOTHER.",fentanyl,sirolimus,False,Neg,0,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,17,20
159,7645,7645,7830,7830,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER (DRUGOTHER, dihydroDRUGOTHER) should be administered with caution in patients receiving DRUG2.",fentanyl,SPRYCEL,True,advise,1,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1,17,34
160,7663,7663,7848,7848,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, or DRUGOTHER (DRUGOTHER, dihydroDRUGOTHER) should be administered with caution in patients receiving DRUG2.",sirolimus,SPRYCEL,True,advise,1,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1,20,34
161,7733,7733,7928,7928,"Antiacid, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, Indanavir, DRUGOTHER, DRUG1, Phenobarbitol, DRUGOTHER, DRUGOTHER, DRUGOTHER, Ritanovir, DRUG2.",Phenytoin,Saquinavir,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,7,13
162,7885,7885,8083,8083,"DRUG1: In post-marketing experience, there have been reports of both increases and decreases in DRUG2 levels with DRUGOTHER co-administration, leading to alterations in seizure control.",Phenytoin,phenytoin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,0,14
163,7939,7939,8137,8137,"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of DRUG1 (DRUGOTHER) and agents for migraine therapy, such as DRUGOTHER (DRUG2) and DRUGOTHER.",selective serotonin reuptake inhibitors,sumatriptan succinate,True,effect,2,NCCC1=CNC2=CC=C(O)C=C12,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C.C(CC(=O)O)C(=O)O,18,28
164,8017,8017,8222,8222,DRUG1: DRUGOTHER may delay intestinal absorption of DRUG2.,Ethosuximide,ethosuximide,False,Neg,0,CCC1(C)CC(=O)NC1=O,CCC1(C)CC(=O)NC1=O,0,7
165,8019,8019,8224,8224,"DRUG1: DRUG1 blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of DRUGOTHER.",Haloperidol,Haloperidol,False,Neg,0,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1,0,-1
166,8026,8026,8231,8231,DRUG1: DRUGOTHER potentiate the analgesic effect of DRUG2.,Meperidine,meperidine,False,Neg,0,CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,0,7
167,8038,8038,8246,8246,DRUG1: DRUGOTHER may delay intestinal absorption of DRUG2;,Phenytoin,phenytoin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,0,7
168,8263,8263,8476,8476,"conversely, DRUG1 may interfere with DRUGOTHER (i.e., DRUG2, DRUGOTHER).",diethylpropion,guanethidine,True,int,3,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,C1CCCN(CCC1)CCN=C(N)N,1,7
169,8286,8286,8503,8503,"DRUG1: In normal volunteers, concomitant administration of DRUGOTHER and DRUG2 resulted in significantly increased plasma levels of DRUG2.",Hydrochlorothiazide,hydrochlorothiazide,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,0,9
170,8287,8287,8504,8504,"DRUG1: In normal volunteers, concomitant administration of DRUGOTHER and DRUG2 resulted in significantly increased plasma levels of DRUG2.",Hydrochlorothiazide,hydrochlorothiazide,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,0,9
171,8290,8290,8507,8507,"DRUGOTHER: In normal volunteers, concomitant administration of DRUGOTHER and DRUG1 resulted in significantly increased plasma levels of DRUG1.",hydrochlorothiazide,hydrochlorothiazide,False,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,9,-1
172,8293,8293,8510,8510,"DRUG1: In normal volunteers, the concomitant administration of DRUGOTHER and DRUG2 had no effect on the diuretic activity of DRUG2.",Furosemide,furosemide,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,0,10
173,8294,8294,8511,8511,"DRUG1: In normal volunteers, the concomitant administration of DRUGOTHER and DRUG2 had no effect on the diuretic activity of DRUG2.",Furosemide,furosemide,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,0,10
174,8297,8297,8514,8514,"DRUGOTHER: In normal volunteers, the concomitant administration of DRUGOTHER and DRUG1 had no effect on the diuretic activity of DRUG1.",furosemide,furosemide,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,10,-1
175,8442,8442,8659,8659,"DRUG1: DRUG1 has been reported to cause coronary artery vasospasm, and its effect could be additive with DRUGOTHER  (DRUGOTHER) Injection, USP.",Sumatriptan,Sumatriptan,False,Neg,0,CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1,CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1,0,-1
176,8630,8630,8862,8862,"DRUG1: Following co-administration of two 250-mg DRUGOTHER tablets administered once daily with 200-mg DRUG2 tablets administered twice daily for 10 days to 14 healthy subjects, the steady-state plasma concentration of DRUG2 was not significantly altered.",Theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,0,13
177,8631,8631,8863,8863,"DRUG1: Following co-administration of two 250-mg DRUGOTHER tablets administered once daily with 200-mg DRUG2 tablets administered twice daily for 10 days to 14 healthy subjects, the steady-state plasma concentration of DRUG2 was not significantly altered.",Theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,0,13
178,8634,8634,8866,8866,"DRUGOTHER: Following co-administration of two 250-mg DRUGOTHER tablets administered once daily with 200-mg DRUG1 tablets administered twice daily for 10 days to 14 healthy subjects, the steady-state plasma concentration of DRUG1 was not significantly altered.",theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,13,-1
179,8638,8638,8870,8870,"In general, most patients treated with DRUGOTHER who are receiving concomitant DRUG1 therapy may not require empiric adjustment of DRUG1 dosage or monitoring of DRUG1 plasma concentrations.",theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,11,-1
180,8639,8639,8871,8871,"In general, most patients treated with DRUGOTHER who are receiving concomitant DRUG1 therapy may not require empiric adjustment of DRUG1 dosage or monitoring of DRUG1 plasma concentrations.",theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,11,-1
181,8640,8640,8872,8872,"In general, most patients treated with DRUGOTHER who are receiving concomitant DRUG1 therapy may not require empiric adjustment of DRUG1 dosage or monitoring of DRUG1 plasma concentrations.",theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,11,-1
182,8641,8641,8873,8873,"However, DRUG1 plasma concentrations should be monitored, with dosage adjustment as appropriate, in patients whose pulmonary disease requires maintaining a given DRUG1 plasma concentration for optimal pulmonary function or in patients with DRUG1 concentrations at the higher end of the therapeutic range.",theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,1,-1
183,8642,8642,8874,8874,"However, DRUG1 plasma concentrations should be monitored, with dosage adjustment as appropriate, in patients whose pulmonary disease requires maintaining a given DRUG1 plasma concentration for optimal pulmonary function or in patients with DRUG1 concentrations at the higher end of the therapeutic range.",theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,1,-1
184,8643,8643,8875,8875,"However, DRUG1 plasma concentrations should be monitored, with dosage adjustment as appropriate, in patients whose pulmonary disease requires maintaining a given DRUG1 plasma concentration for optimal pulmonary function or in patients with DRUG1 concentrations at the higher end of the therapeutic range.",theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,1,-1
185,8786,8786,9018,9018,"There was no evidence of drug interactions in clinical studies in which DRUGOTHER was administered concurrently with other drugs, including DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",furosemide,spironolactone,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,21,22
186,8996,8996,9231,9231,"Other Drugs: In healthy volunteers, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, hormone replacement therapy (a combination of conjugated DRUGOTHER and DRUGOTHER), DRUGOTHER (aluminum and DRUGOTHERs) and DRUG2 did not affect the pharmacokinetics of DRUGOTHER.",phenytoin,theophylline,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CN1C2=C(C(=O)N(C1=O)C)NC=N2,6,25
187,9055,9055,9290,9290,"In addition, studies in healthy volunteers have shown that DRUGOTHER does not affect the pharmacokinetics or pharmacodynamics of DRUGOTHER, or the pharmacokinetics of DRUGOTHER (40 mg twice daily), DRUG1, DRUG2, or oral DRUGOTHER.",phenytoin,theophylline,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CN1C2=C(C(=O)N(C1=O)C)NC=N2,28,29
188,9104,9104,9346,9346,"The concomitant use of DRUG1s, vasoconstricting agents (such as DRUG2) and some DRUGOTHER may result in severe hypertension.",vasopressor,ergonovine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](CC)CO,4,9
189,9260,9260,9502,9502,"Inhibitors or substrates of CYP2D6 (i.e., DRUGOTHER, DRUG1 [DRUGOTHER]) may increase the plasma concentration of DRUG2 when administered concomitantly.",selective serotonin reuptake inhibitors,doxepin,True,mechanism,4,NCCC1=CNC2=CC=C(O)C=C12,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,7,15
190,9287,9287,9529,9529,"DRUGOTHER, DRUGOTHER, and DRUG1 decrease the half-life of DRUG2.",phenytoin,doxycycline,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,3,8
191,9373,9373,9615,9615,"Because of the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of DRUG1, DRUGOTHER and DRUG1 should not be co-administered.",thioridazine,thioridazine,False,Neg,0,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,18,-1
192,9398,9398,9640,9640,"Synergism between DRUG1 (e.g., DRUG2), DRUGOTHER, and other DRUGOTHER has been reported.",xanthine bronchodilators,theophylline,False,Neg,0,O=C1NC2=C(NC=N2)C(=O)N1,CN1C2=C(C(=O)N(C1=O)C)NC=N2,2,4
193,9402,9402,9644,9644,"Concurrent administration of DRUG1 and DRUGOTHER, which competes for tubular secretion, has been shown to increase the plasma half-life of DRUG1 .",dyphylline,dyphylline,False,Neg,0,CN1C2=C(N(CC(O)CO)C=N2)C(=O)N(C)C1=O,CN1C2=C(N(CC(O)CO)C=N2)C(=O)N(C)C1=O,3,-1
194,9478,9478,9720,9720,DRUGOTHER: DRUG1/DRUG2 combination,Saquinavir,ritonavir,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1,1
195,9605,9605,9847,9847,DRUG1: DRUGOTHER is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of DRUG2.,Caffeine,methylxanthines,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,O=C1NC2=C(NC=N2)C(=O)N1,0,16
196,9610,9610,9852,9852,"In a multiple-dose study, DRUGOTHER caused a dose-related increase in the mean elimination half-life of DRUG1, thereby decreasing the clearance of DRUG1 by up to 80% and leading to a five-fold increase in the AUC and the half-life of DRUG1.",caffeine,caffeine,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,15,-1
197,9611,9611,9853,9853,"In a multiple-dose study, DRUGOTHER caused a dose-related increase in the mean elimination half-life of DRUG1, thereby decreasing the clearance of DRUG1 by up to 80% and leading to a five-fold increase in the AUC and the half-life of DRUG1.",caffeine,caffeine,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,15,-1
198,9612,9612,9854,9854,"In a multiple-dose study, DRUGOTHER caused a dose-related increase in the mean elimination half-life of DRUG1, thereby decreasing the clearance of DRUG1 by up to 80% and leading to a five-fold increase in the AUC and the half-life of DRUG1.",caffeine,caffeine,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,15,-1
199,9616,9616,9858,9858,DRUG1-related adverse effects have occurred in patients consuming DRUG2 while on therapy with DRUGOTHER.,Caffeine,caffeine,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,0,8
200,9649,9649,9891,9891,DRUG1: DRUGOTHER is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of DRUG2.,Theophylline,methylxanthines,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,O=C1NC2=C(NC=N2)C(=O)N1,0,16
201,9653,9653,9895,9895,DRUGOTHER interferes with the metabolism of DRUG1 resulting in a 42% to 74% dose-related decrease in DRUG1 clearance and a subsequent 260% to 350% increase in serum DRUG1 levels.,theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,6,-1
202,9654,9654,9896,9896,DRUG1-related adverse effects have occurred in patients when DRUG2 and DRUGOTHER were coadministered.,Theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,0,8
203,9801,9801,10044,10044,"In clinical trials, DRUGOTHER was used with DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER, and supplemental DRUGOTHER.In a pharmacokinetic substudy in patients with congestive heart failure receiving DRUG1 or DRUGOTHER in whom therapy with DRUGOTHER was initiated, apparent oral clearance values for DRUG1 (n = 23) and DRUGOTHER (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.",furosemide,furosemide,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,25,-1
204,9823,9823,10066,10066,"Because DRUG1 is not metabolized by the cytochrome P450 system, inhibitors of CYP450 enzyme would not be expected to affect its metabolism, and DRUGOTHER and DRUGOTHER, potent inhibitors of CYP3A and 2C9, respectively, have been shown to have no effect on DRUG1 pharmacokinetics.",eprosartan,eprosartan,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,1,-1
205,9828,9828,10071,10071,DRUG1 (up to 400 mg b.i.d. or 800 mg q.d.) doses have been safely used concomitantly with a DRUGOTHER (DRUG2).,Eprosartan,hydrochlorothiazide,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,0,19
206,9899,9899,10142,10142,"Caution should be used when administering or taking DRUGOTHER with DRUGOTHER and other strong CYP3A4 inhibitors such as, but not limited to, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER .",nefazodone,ritonavir,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,26,28
207,9900,9900,10143,10143,"Caution should be used when administering or taking DRUGOTHER with DRUGOTHER and other strong CYP3A4 inhibitors such as, but not limited to, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER .",nefazodone,saquinavir,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,26,29
208,9901,9901,10144,10144,"Caution should be used when administering or taking DRUGOTHER with DRUGOTHER and other strong CYP3A4 inhibitors such as, but not limited to, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER (DRUGOTHER), and DRUGOTHER .",nefazodone,telithromycin,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,26,30
209,9911,9911,10154,10154,"Caution should be used when administering or taking DRUGOTHER with DRUGOTHER and other strong CYP3A4 inhibitors such as, but not limited to, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER .",ritonavir,saquinavir,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,28,29
210,9912,9912,10155,10155,"Caution should be used when administering or taking DRUGOTHER with DRUGOTHER and other strong CYP3A4 inhibitors such as, but not limited to, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER (DRUGOTHER), and DRUGOTHER .",ritonavir,telithromycin,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,28,30
211,9916,9916,10159,10159,"Caution should be used when administering or taking DRUGOTHER with DRUGOTHER and other strong CYP3A4 inhibitors such as, but not limited to, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER (DRUGOTHER), and DRUGOTHER .",saquinavir,telithromycin,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,29,30
212,9956,9956,10199,10199,DRUGOTHER use in patients who are receiving high doses of DRUG1 may be associated with an increase in serum DRUG1 levels and potential DRUG1 toxicity.,theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,10,-1
213,9957,9957,10200,10200,DRUGOTHER use in patients who are receiving high doses of DRUG1 may be associated with an increase in serum DRUG1 levels and potential DRUG1 toxicity.,theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,10,-1
214,9958,9958,10201,10201,DRUGOTHER use in patients who are receiving high doses of DRUG1 may be associated with an increase in serum DRUG1 levels and potential DRUG1 toxicity.,theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,10,-1
215,9959,9959,10202,10202,"In case of DRUG1 toxicity and/or elevated serum DRUG1 levels, the dose of DRUG1 should be reduced while the patient is receiving concomitant DRUGOTHER therapy.",theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,3,-1
216,9960,9960,10203,10203,"In case of DRUG1 toxicity and/or elevated serum DRUG1 levels, the dose of DRUG1 should be reduced while the patient is receiving concomitant DRUGOTHER therapy.",theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,3,-1
217,9962,9962,10205,10205,"In case of DRUG1 toxicity and/or elevated serum DRUG1 levels, the dose of DRUG1 should be reduced while the patient is receiving concomitant DRUGOTHER therapy.",theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,3,-1
218,10128,10128,10371,10371,"DRUG1 - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a DRUG2 (DRUGOTHER) and DRUGOTHER.",Sumatriptan,selective serotonin reuptake inhibitor,False,Neg,0,CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1,NCCC1=CNC2=CC=C(O)C=C12,0,20
219,10129,10129,10372,10372,"DRUG1 - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a DRUGOTHER (DRUGOTHER) and DRUG2.",Sumatriptan,sumatriptan,False,Neg,0,CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,0,23
220,10130,10130,10373,10373,"DRUGOTHER - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a DRUG1 (DRUGOTHER) and DRUG2.",selective serotonin reuptake inhibitor,sumatriptan,True,effect,2,NCCC1=CNC2=CC=C(O)C=C12,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,20,23
221,10153,10153,10396,10396,DRUG1 - Combined administration of racemic DRUGOTHER (40 mg/day for 21 days) and the CYP1A2 substrate DRUG2 (single dose of 300 mg) did not affect the pharmacokinetics of DRUG2.,Theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,0,16
222,10154,10154,10397,10397,DRUG1 - Combined administration of racemic DRUGOTHER (40 mg/day for 21 days) and the CYP1A2 substrate DRUG2 (single dose of 300 mg) did not affect the pharmacokinetics of DRUG2.,Theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,0,16
223,10157,10157,10400,10400,DRUGOTHER - Combined administration of racemic DRUGOTHER (40 mg/day for 21 days) and the CYP1A2 substrate DRUG1 (single dose of 300 mg) did not affect the pharmacokinetics of DRUG1.,theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,16,-1
224,10194,10194,10437,10437,"DRUG1 - Combined administration of a single dose of DRUG2 (600 mg), both a CYP3A4 substrate and a potent inhibitor of CYP3A4, and DRUGOTHER (20 mg) did not affect the pharmacokinetics of either DRUG2 or DRUGOTHER.",Ritonavir,ritonavir,False,Neg,0,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,0,9
225,10196,10196,10439,10439,"DRUG1 - Combined administration of a single dose of DRUG2 (600 mg), both a CYP3A4 substrate and a potent inhibitor of CYP3A4, and DRUGOTHER (20 mg) did not affect the pharmacokinetics of either DRUG2 or DRUGOTHER.",Ritonavir,ritonavir,False,Neg,0,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,0,9
226,10199,10199,10442,10442,"DRUGOTHER - Combined administration of a single dose of DRUG1 (600 mg), both a CYP3A4 substrate and a potent inhibitor of CYP3A4, and DRUGOTHER (20 mg) did not affect the pharmacokinetics of either DRUG1 or DRUGOTHER.",ritonavir,ritonavir,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,9,-1
227,10393,10393,10636,10636,"Other strong inhibitors of CYP3A4 (e.g., DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER) would be expected to behave similarly.",nefazodone,ritonavir,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,8,10
228,10444,10444,10687,10687,"Since DRUGOTHER (DRUG1) may interact with concurrently administered DRUGOTHER, periodic serum level determinations of these drugs may be necessary (eg, DRUG1 may elevate DRUGOTHER serum levels and DRUGOTHER has been reported to both increase and decrease DRUG1 levels).",ethosuximide,ethosuximide,False,Neg,0,CCC1(C)CC(=O)NC1=O,CCC1(C)CC(=O)NC1=O,2,-1
229,10445,10445,10688,10688,"Since DRUGOTHER (DRUG1) may interact with concurrently administered DRUGOTHER, periodic serum level determinations of these drugs may be necessary (eg, DRUG1 may elevate DRUG2 serum levels and DRUGOTHER has been reported to both increase and decrease DRUG1 levels).",ethosuximide,phenytoin,False,Neg,0,CCC1(C)CC(=O)NC1=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,2,23
230,10447,10447,10690,10690,"Since DRUGOTHER (DRUG1) may interact with concurrently administered DRUGOTHER, periodic serum level determinations of these drugs may be necessary (eg, DRUG1 may elevate DRUGOTHER serum levels and DRUGOTHER has been reported to both increase and decrease DRUG1 levels).",ethosuximide,ethosuximide,False,Neg,0,CCC1(C)CC(=O)NC1=O,CCC1(C)CC(=O)NC1=O,2,-1
231,10448,10448,10691,10691,"Since DRUGOTHER (DRUG1) may interact with concurrently administered DRUGOTHER, periodic serum level determinations of these drugs may be necessary (eg, DRUG1 may elevate DRUG2 serum levels and DRUGOTHER has been reported to both increase and decrease DRUG1 levels).",ethosuximide,phenytoin,True,mechanism,4,CCC1(C)CC(=O)NC1=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,2,23
232,10450,10450,10693,10693,"Since DRUGOTHER (DRUG1) may interact with concurrently administered DRUGOTHER, periodic serum level determinations of these drugs may be necessary (eg, DRUG1 may elevate DRUGOTHER serum levels and DRUGOTHER has been reported to both increase and decrease DRUG1 levels).",ethosuximide,ethosuximide,False,Neg,0,CCC1(C)CC(=O)NC1=O,CCC1(C)CC(=O)NC1=O,2,-1
233,10452,10452,10695,10695,"Since DRUGOTHER (DRUG2) may interact with concurrently administered DRUGOTHER, periodic serum level determinations of these drugs may be necessary (eg, DRUG2 may elevate DRUG1 serum levels and DRUGOTHER has been reported to both increase and decrease DRUG2 levels).",phenytoin,ethosuximide,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC1(C)CC(=O)NC1=O,23,2
234,10503,10503,10754,10754,"DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2): Increase the metabolism of DRUGOTHER and/or some DRUGOTHER, leading to possible decrease in contraceptive effectiveness.",phenytoin,topiramate,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,4,5
235,10612,10612,10872,10872,"DRUG1: DRUGOTHER may inhibit the metabolism of DRUG2, leading to increased plasma concentrations.",Theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,0,7
236,10633,10633,10893,10893,DRUGOTHER / NUTRITION / HERB INTERACTIONS: Food: CNS effects of DRUG1 may be enhanced if DRUGOTHER are used concurrently with DRUG1.,caffeine,caffeine,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,10,-1
237,10652,10652,10912,10912,DRUGOTHER: Etodolac has no apparent pharmacokinetic interaction when administered with DRUG1 or DRUG2.,furosemide,hydrochlorothiazide,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,10,12
238,10655,10655,10915,10915,"Nevertheless, clinical studies, as well as postmarketing observations have shown that DRUGOTHER can reduce the natriuretic effect of DRUG1 and DRUG2 in some patients.",furosemide,thiazides,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,18,20
239,10664,10664,10924,10924,DRUG1: DRUGOTHER has no apparent pharmacokinetic interaction when administered with DRUG2.,Phenytoin,phenytoin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,0,10
240,10846,10846,11109,11109,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUG1, DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",tetracycline,Dilantin,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,14,16
241,10850,10850,11113,11113,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUG1, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",tetracycline,Topamax,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,14,20
242,10865,10865,11128,11128,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUG1, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",tetracycline,Fortovase,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,14,40
243,10866,10866,11129,11129,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUG1, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",tetracycline,Invirase,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,14,41
244,10868,10868,11131,11131,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUG1, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",tetracycline,Norvir,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,14,43
245,10880,10880,11143,11143,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUG1, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUG2 (DRUGOTHER), and DRUGOTHER.",tetracycline,theophylline,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,14,58
246,10881,10881,11144,11144,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUG1, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUG2), and DRUGOTHER.",tetracycline,Theo-Dur,False,Neg,0,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CN1C2=C(NC=N2)C(=O)N(C)C1=O,14,59
247,10923,10923,11186,11186,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Dilantin,Topamax,False,Neg,0,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,16,20
248,10938,10938,11201,11201,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Dilantin,Fortovase,False,Neg,0,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,16,40
249,10939,10939,11202,11202,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Dilantin,Invirase,False,Neg,0,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,16,41
250,10941,10941,11204,11204,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Dilantin,Norvir,False,Neg,0,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,16,43
251,10953,10953,11216,11216,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUG2 (DRUGOTHER), and DRUGOTHER.",Dilantin,theophylline,False,Neg,0,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,CN1C2=C(C(=O)N(C1=O)C)NC=N2,16,58
252,10954,10954,11217,11217,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUG2), and DRUGOTHER.",Dilantin,Theo-Dur,False,Neg,0,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,CN1C2=C(NC=N2)C(=O)N(C)C1=O,16,59
253,11072,11072,11335,11335,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Topamax,Fortovase,False,Neg,0,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,20,40
254,11073,11073,11336,11336,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Topamax,Invirase,False,Neg,0,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,20,41
255,11075,11075,11338,11338,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Topamax,Norvir,False,Neg,0,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,20,43
256,11087,11087,11350,11350,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUG2 (DRUGOTHER), and DRUGOTHER.",Topamax,theophylline,False,Neg,0,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,20,58
257,11088,11088,11351,11351,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUG2), and DRUGOTHER.",Topamax,Theo-Dur,False,Neg,0,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,CN1C2=C(NC=N2)C(=O)N(C)C1=O,20,59
258,11433,11433,11696,11696,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Fortovase,Invirase,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,40,41
259,11435,11435,11698,11698,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Fortovase,Norvir,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,40,43
260,11447,11447,11710,11710,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUG2 (DRUGOTHER), and DRUGOTHER.",Fortovase,theophylline,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,CN1C2=C(C(=O)N(C1=O)C)NC=N2,40,58
261,11448,11448,11711,11711,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUG2), and DRUGOTHER.",Fortovase,Theo-Dur,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,CN1C2=C(NC=N2)C(=O)N(C)C1=O,40,59
262,11451,11451,11714,11714,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUGOTHER), and DRUGOTHER.",Invirase,Norvir,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,41,43
263,11463,11463,11726,11726,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUG2 (DRUGOTHER), and DRUGOTHER.",Invirase,theophylline,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,CN1C2=C(C(=O)N(C1=O)C)NC=N2,41,58
264,11464,11464,11727,11727,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUG2), and DRUGOTHER.",Invirase,Theo-Dur,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,CN1C2=C(NC=N2)C(=O)N(C)C1=O,41,59
265,11492,11492,11755,11755,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUG2 (DRUGOTHER), and DRUGOTHER.",Norvir,theophylline,False,Neg,0,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,CN1C2=C(C(=O)N(C1=O)C)NC=N2,43,58
266,11493,11493,11756,11756,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUGOTHER (DRUG2), and DRUGOTHER.",Norvir,Theo-Dur,False,Neg,0,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,CN1C2=C(NC=N2)C(=O)N(C)C1=O,43,59
267,11583,11583,11846,11846,"DRUGOTHER may interact with the following medications: DRUGOTHER (DRUGOTHER), DRUGOTHER such as DRUGOTHER and DRUGOTHER, DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), HIV drugs classified as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), St. Johns wort, DRUGOTHER, DRUG1 (DRUG2), and DRUGOTHER.",theophylline,Theo-Dur,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(NC=N2)C(=O)N(C)C1=O,58,59
268,11607,11607,11880,11880,"Compounds tested in man include DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER and DRUGOTHER.",theophylline,phenytoin,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,6,7
269,11624,11624,11897,11897,Specific Effects of DRUGOTHER  on Other DRUGOTHER DRUG1: DRUGOTHER  causes an increase in steady-state DRUG2 plasma concentrations.,Phenytoin,phenytoin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,8,16
270,11626,11626,11899,11899,"In 10 otherwise healthy subjects with epilepsy ingesting DRUG1, the steadystate trough (Cmin) DRUG1 plasma concentration was 17 5 micrograms/mL.",phenytoin,phenytoin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,8,-1
271,11629,11629,11902,11902,"In order to maintain DRUG1 levels, limit adverse experiences, and achieve the DRUGOTHER dose of 3600 mg/day, a DRUG1 dose reduction of approximately 40% was necessary for eight of these 10 subjects.",phenytoin,phenytoin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,4,-1
272,11632,11632,11905,11905,"In a controlled clinical trial, a 20% reduction of the DRUG1 dose at the initiation of DRUGOTHER  therapy resulted in DRUG1 levels comparable to those prior to DRUGOTHER  administration.",phenytoin,phenytoin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,10,-1
273,11671,11671,11944,11944,"Effects of Other DRUGOTHER on DRUGOTHER  DRUG1: DRUG1 causes an approximate doubling of the clearance of DRUGOTHER  (DRUGOTHER) at steady state and, therefore, the addition of DRUGOTHER causes an approximate 45% decrease in the steady-state trough concentrations of DRUGOTHER  as compared to the same dose of DRUGOTHER  given as monotherapy.",Phenytoin,Phenytoin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,7,-1
274,11674,11674,11947,11947,"Effects of Other DRUGOTHER on DRUGOTHER  DRUG1: DRUG1 causes an approximate doubling of the clearance of DRUGOTHER  (DRUGOTHER) at steady state and, therefore, the addition of DRUG2 causes an approximate 45% decrease in the steady-state trough concentrations of DRUGOTHER  as compared to the same dose of DRUGOTHER  given as monotherapy.",Phenytoin,phenytoin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,7,28
275,11679,11679,11952,11952,"Effects of Other DRUGOTHER on DRUGOTHER  DRUG1: DRUG1 causes an approximate doubling of the clearance of DRUGOTHER  (DRUGOTHER) at steady state and, therefore, the addition of DRUG2 causes an approximate 45% decrease in the steady-state trough concentrations of DRUGOTHER  as compared to the same dose of DRUGOTHER  given as monotherapy.",Phenytoin,phenytoin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,7,28
276,11812,11812,12085,12085,"Concomitant administration of DRUGOTHER (equivalent to 145mg DRUGOTHER) with DRUG1 (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for DRUG1 by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3 -hydroxy-iso-DRUG1 by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.",pravastatin,pravastatin,False,Neg,0,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,9,-1
277,11830,11830,12105,12105,"The concomitant use of transdermal DRUG1 with DRUG2 or other potent 3A4 inhibitors such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and nefazadone may result in an increase in DRUG1 plasma concentrations.",fentanyl,ritonavir,True,mechanism,4,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,5,7
278,11836,11836,12111,12111,"The concomitant use of transdermal DRUG1 with DRUGOTHER or other potent 3A4 inhibitors such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and nefazadone may result in an increase in DRUG1 plasma concentrations.",fentanyl,fentanyl,False,Neg,0,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,5,-1
279,11842,11842,12117,12117,"The concomitant use of transdermal DRUG2 with DRUG1 or other potent 3A4 inhibitors such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and nefazadone may result in an increase in DRUG2 plasma concentrations.",ritonavir,fentanyl,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,7,5
280,11863,11863,12138,12138,"The concomitant use of other CYP3A4 inhibitors such as DRUGOTHER and DRUGOTHER with transdermal DRUG1 may also result in an increase in DRUG1 plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.",fentanyl,fentanyl,False,Neg,0,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,14,-1
281,11873,11873,12148,12148,"DRUGOTHER: The concomitant use of DRUG1  (DRUG2 transdermal system) with other DRUGOTHER, including but not limited to other DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (e.g., DRUGOTHER), general DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",DURAGESIC,fentanyl,False,Neg,0,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,5,7
282,12378,12378,12659,12659,"DRUG1: The effect of steady-state DRUGOTHER l50 mg bid on the pharmacokinetics of a single dose of DRUG1 (375 mg) as 442 mg DRUGOTHER was evaluated in 12 healthy non-smoking, male volunteers.",Theophylline,Theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,0,-1
283,12384,12384,12665,12665,"Therefore, if DRUG1 is co-administered with DRUGOTHER, its dose should be reduced to one third of the usual daily maintenance dose and plasma concentrations of DRUG1 should to monitored.",theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,2,-1
284,12491,12491,12772,12772,"DRUGOTHER, DRUG1 and DRUGOTHER: Concomitant treatment with DRUG2, DRUGOTHER, or DRUGOTHER may potentiate a possible hypokalemic effect of  DRUGOTHER",Methylxanthines,xanthine derivatives,False,Neg,0,O=C1NC2=C(NC=N2)C(=O)N1,O=C1NC2=C(NC=N2)C(=O)N1,1,7
285,12642,12642,12923,12923,No drugs are known to interfere with the conversion of DRUG1 to DRUG2.,fosphenytoin,phenytoin,False,Neg,0,O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,10,12
286,12643,12643,12924,12924,"Conversion could be affected by alterations in the level of phosphatase activity, but given the abundance and wide distribution of phosphatases in the body it is unlikely that drugs would affect this activity enough to affect conversion of DRUG1 to DRUG2.",fosphenytoin,phenytoin,False,Neg,0,O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,38,40
287,12644,12644,12925,12925,"The pharmacokinetics and protein binding of DRUG1, DRUG2, and DRUGOTHER were not altered when DRUGOTHER and DRUGOTHER were concurrently administered in single submaximal doses.",fosphenytoin,phenytoin,False,Neg,0,O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,6,7
288,12647,12647,12928,12928,"The pharmacokinetics and protein binding of DRUG1, DRUGOTHER, and DRUGOTHER were not altered when DRUGOTHER and DRUG2 were concurrently administered in single submaximal doses.",fosphenytoin,Cerebyx,False,Neg,0,O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,6,16
289,12650,12650,12931,12931,"The pharmacokinetics and protein binding of fosDRUG1, DRUG1, and DRUGOTHER were not altered when DRUGOTHER and DRUG2 were concurrently administered in single submaximal doses.",phenytoin,Cerebyx,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,6,16
290,12654,12654,12935,12935,The most significant drug interactions following administration of DRUG1 are expected to occur with drugs that interact with DRUG2.,Cerebyx,phenytoin,False,Neg,0,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,8,18
291,12663,12663,12944,12944,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUG1 concentrations include: acute DRUGOTHER intake, DRUGOTHER, chboramphenicol, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER",phenytoin,ethosuximide,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCC1(C)CC(=O)NC1=O,15,29
292,12671,12671,12952,12952,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUG1 concentrations include: acute DRUGOTHER intake, DRUGOTHER, chboramphenicol, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER",phenytoin,sulfonamides,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,15,39
293,12797,12797,13078,13078,"The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma DRUGOTHER concentrations include: acute DRUGOTHER intake, DRUGOTHER, chboramphenicol, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER",ethosuximide,sulfonamides,False,Neg,0,CCC1(C)CC(=O)NC1=O,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,29,39
294,12862,12862,13143,13143," Drugs whose efficacy is impaired by DRUG1 include: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",phenytoin,doxycycline,True,effect,2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,7,13
295,12864,12864,13145,13145," Drugs whose efficacy is impaired by DRUG1 include: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",phenytoin,furosemide,True,effect,2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,7,15
296,12868,12868,13149,13149," Drugs whose efficacy is impaired by DRUG1 include: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER.",phenytoin,theophylline,True,effect,2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CN1C2=C(C(=O)N(C1=O)C)NC=N2,7,20
297,12898,12898,13179,13179," Drugs whose efficacy is impaired by DRUGOTHER include: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",doxycycline,furosemide,False,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,13,15
298,12902,12902,13183,13183," Drugs whose efficacy is impaired by DRUGOTHER include: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER.",doxycycline,theophylline,False,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CN1C2=C(C(=O)N(C1=O)C)NC=N2,13,20
299,12913,12913,13194,13194," Drugs whose efficacy is impaired by DRUGOTHER include: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, Oral DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER.",furosemide,theophylline,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CN1C2=C(C(=O)N(C1=O)C)NC=N2,15,20
300,12925,12925,13206,13206,Care should be taken when using immunoanalytical methods to measure plasma DRUG1 concentrations following DRUG2 administration.,phenytoin,Cerebyx,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,11,14
301,12952,12952,13236,13236,Tablets Simultaneous administration of DRUGOTHER and DRUG1 tablets may reduce the natriuretic and antihypertensive effects of DRUG1.,furosemide,furosemide,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,6,-1
302,12958,12958,13242,13242,Patients receiving both DRUGOTHER and DRUG1 should be observed closely to determine if the desired diuretic and/or antihypertensive effect of DRUG1 is achieved.,furosemide,furosemide,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,5,-1
303,12959,12959,13243,13243,"DRUG1: In a single (400 mg) and multiple dose (400 mg TID) study of DRUGOTHER in epileptic patients (N=8) maintained on DRUG2 monotherapy for at least 2 months, DRUGOTHER had no effect on the steady-state trough plasma concentrations of DRUG2 and DRUG2 had no effect on DRUGOTHER pharmacokinetics.",Phenytoin,phenytoin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,0,21
304,12960,12960,13244,13244,"DRUG1: In a single (400 mg) and multiple dose (400 mg TID) study of DRUGOTHER in epileptic patients (N=8) maintained on DRUGOTHER monotherapy for at least 2 months, DRUG2 had no effect on the steady-state trough plasma concentrations of DRUGOTHER and DRUGOTHER had no effect on DRUG2 pharmacokinetics.",Phenytoin,gabapentin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,NCC1(CC(O)=O)CCCCC1,0,28
305,12961,12961,13245,13245,"DRUG1: In a single (400 mg) and multiple dose (400 mg TID) study of DRUGOTHER in epileptic patients (N=8) maintained on DRUG2 monotherapy for at least 2 months, DRUGOTHER had no effect on the steady-state trough plasma concentrations of DRUG2 and DRUG2 had no effect on DRUGOTHER pharmacokinetics.",Phenytoin,phenytoin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,0,21
306,12962,12962,13246,13246,"DRUG1: In a single (400 mg) and multiple dose (400 mg TID) study of DRUGOTHER in epileptic patients (N=8) maintained on DRUG2 monotherapy for at least 2 months, DRUGOTHER had no effect on the steady-state trough plasma concentrations of DRUG2 and DRUG2 had no effect on DRUGOTHER pharmacokinetics.",Phenytoin,phenytoin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,0,21
307,12963,12963,13247,13247,"DRUG1: In a single (400 mg) and multiple dose (400 mg TID) study of DRUGOTHER in epileptic patients (N=8) maintained on DRUGOTHER monotherapy for at least 2 months, DRUG2 had no effect on the steady-state trough plasma concentrations of DRUGOTHER and DRUGOTHER had no effect on DRUG2 pharmacokinetics.",Phenytoin,gabapentin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,NCC1(CC(O)=O)CCCCC1,0,28
308,12964,12964,13248,13248,"DRUGOTHER: In a single (400 mg) and multiple dose (400 mg TID) study of DRUGOTHER in epileptic patients (N=8) maintained on DRUG1 monotherapy for at least 2 months, DRUG2 had no effect on the steady-state trough plasma concentrations of DRUG1 and DRUG1 had no effect on DRUG2 pharmacokinetics.",phenytoin,gabapentin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,NCC1(CC(O)=O)CCCCC1,21,28
309,12965,12965,13249,13249,"DRUGOTHER: In a single (400 mg) and multiple dose (400 mg TID) study of DRUGOTHER in epileptic patients (N=8) maintained on DRUG1 monotherapy for at least 2 months, DRUGOTHER had no effect on the steady-state trough plasma concentrations of DRUG1 and DRUG1 had no effect on DRUGOTHER pharmacokinetics.",phenytoin,phenytoin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,21,-1
310,12966,12966,13250,13250,"DRUGOTHER: In a single (400 mg) and multiple dose (400 mg TID) study of DRUGOTHER in epileptic patients (N=8) maintained on DRUG1 monotherapy for at least 2 months, DRUGOTHER had no effect on the steady-state trough plasma concentrations of DRUG1 and DRUG1 had no effect on DRUGOTHER pharmacokinetics.",phenytoin,phenytoin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,21,-1
311,12967,12967,13251,13251,"DRUGOTHER: In a single (400 mg) and multiple dose (400 mg TID) study of DRUGOTHER in epileptic patients (N=8) maintained on DRUG1 monotherapy for at least 2 months, DRUG2 had no effect on the steady-state trough plasma concentrations of DRUG1 and DRUG1 had no effect on DRUG2 pharmacokinetics.",phenytoin,gabapentin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,NCC1(CC(O)=O)CCCCC1,21,28
312,12968,12968,13252,13252,"DRUGOTHER: In a single (400 mg) and multiple dose (400 mg TID) study of DRUGOTHER in epileptic patients (N=8) maintained on DRUG2 monotherapy for at least 2 months, DRUG1 had no effect on the steady-state trough plasma concentrations of DRUG2 and DRUG2 had no effect on DRUG1 pharmacokinetics.",gabapentin,phenytoin,False,Neg,0,NCC1(CC(O)=O)CCCCC1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,28,21
313,12969,12969,13253,13253,"DRUGOTHER: In a single (400 mg) and multiple dose (400 mg TID) study of DRUGOTHER in epileptic patients (N=8) maintained on DRUG2 monotherapy for at least 2 months, DRUG1 had no effect on the steady-state trough plasma concentrations of DRUG2 and DRUG2 had no effect on DRUG1 pharmacokinetics.",gabapentin,phenytoin,False,Neg,0,NCC1(CC(O)=O)CCCCC1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,28,21
314,12970,12970,13254,13254,"DRUGOTHER: In a single (400 mg) and multiple dose (400 mg TID) study of DRUGOTHER in epileptic patients (N=8) maintained on DRUGOTHER monotherapy for at least 2 months, DRUG1 had no effect on the steady-state trough plasma concentrations of DRUGOTHER and DRUGOTHER had no effect on DRUG1 pharmacokinetics.",gabapentin,gabapentin,False,Neg,0,NCC1(CC(O)=O)CCCCC1,NCC1(CC(O)=O)CCCCC1,28,-1
315,12971,12971,13255,13255,"DRUGOTHER: In a single (400 mg) and multiple dose (400 mg TID) study of DRUGOTHER in epileptic patients (N=8) maintained on DRUG1 monotherapy for at least 2 months, DRUGOTHER had no effect on the steady-state trough plasma concentrations of DRUG1 and DRUG1 had no effect on DRUGOTHER pharmacokinetics.",phenytoin,phenytoin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,21,-1
316,12972,12972,13256,13256,"DRUGOTHER: In a single (400 mg) and multiple dose (400 mg TID) study of DRUGOTHER in epileptic patients (N=8) maintained on DRUG1 monotherapy for at least 2 months, DRUG2 had no effect on the steady-state trough plasma concentrations of DRUG1 and DRUG1 had no effect on DRUG2 pharmacokinetics.",phenytoin,gabapentin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,NCC1(CC(O)=O)CCCCC1,21,28
317,12973,12973,13257,13257,"DRUGOTHER: In a single (400 mg) and multiple dose (400 mg TID) study of DRUGOTHER in epileptic patients (N=8) maintained on DRUG1 monotherapy for at least 2 months, DRUG2 had no effect on the steady-state trough plasma concentrations of DRUG1 and DRUG1 had no effect on DRUG2 pharmacokinetics.",phenytoin,gabapentin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,NCC1(CC(O)=O)CCCCC1,21,28
318,12993,12993,13277,13277,"DRUGOTHER: A literature article reported that when a 60-mg controlled-release DRUGOTHER capsule was administered 2 hours prior to a 600-mg DRUGOTHER  capsule (N=12), mean DRUG1 AUC increased by 44% compared to DRUG1 administered without DRUGOTHER.",gabapentin,gabapentin,False,Neg,0,NCC1(CC(O)=O)CCCCC1,NCC1(CC(O)=O)CCCCC1,25,-1
319,13034,13034,13318,13318,"Administration of repeat doses of DRUGOTHER had no effect on the repeat dose pharmacokinetics of DRUG1, DRUGOTHER or an DRUGOTHER/levonorgestrol oral DRUG2 in healthy subjects.",theophylline,contraceptive product,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,15,21
320,13119,13119,13403,13403,"These drugs include the DRUG1 and other DRUGOTHER, DRUGOTHER, phe-nothiazines, DRUGOTHER, DRUGOTHER, oral DRUGOTHER, DRUG2, DRUGOTHER, sympathomimet-ics, DRUGOTHER, and DRUGOTHER.",thiazides,phenytoin,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,4,14
321,13293,13293,13577,13577,"- a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUG2), and DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER);",oxaprozin,Daypro,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,25,26
322,13295,13295,13579,13579,"- a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), and DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER);",oxaprozin,Anaprox,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,25,29
323,13296,13296,13580,13580,"- a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUGOTHER), and DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER);",oxaprozin,Naprosyn,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,25,30
324,13299,13299,13583,13583,"- a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), and DRUGOTHER (DRUG2, DRUGOTHER, DRUGOTHER);",Daypro,Anaprox,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,26,29
325,13300,13300,13584,13584,"- a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUG1), and DRUGOTHER (DRUGOTHER, DRUG2, DRUGOTHER);",Daypro,Naprosyn,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,26,30
326,13305,13305,13589,13589,"- a DRUGOTHER (DRUGOTHER) such as DRUGOTHER (DRUGOTHER, DRUGOTHER, DRUGOTHER, others), DRUGOTHER (DRUGOTHER, DRUGOTHER KT, DRUGOTHER), DRUGOTHER (DRUGOTHER, DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), and DRUGOTHER (DRUG1, DRUG2, DRUGOTHER);",Anaprox,Naprosyn,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,29,30
327,13473,13473,13757,13757,- DRUG1 (DRUG2);,phenytoin,Dilantin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,1,2
328,13525,13525,13809,13809,"These drugs include the DRUG1 and other DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, oral DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER.",thiazides,phenytoin,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,4,14
329,13589,13589,13873,13873,"DRUG1 DRUG2 DRUGOTHER, like other DRUGOTHER, may inhibit the metabolism of DRUGOTHER and DRUGOTHER.",Caffeine,Theobromine,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CN1C=NC2=C1C(=O)NC(=O)N2C,0,1
330,13591,13591,13875,13875,"DRUG1 DRUGOTHER DRUGOTHER, like other DRUGOTHER, may inhibit the metabolism of DRUG2 and DRUGOTHER.",Caffeine,caffeine,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,0,11
331,13592,13592,13876,13876,"DRUG1 DRUGOTHER DRUGOTHER, like other DRUGOTHER, may inhibit the metabolism of DRUGOTHER and DRUG2.",Caffeine,theobromine,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CN1C=NC2=C1C(=O)NC(=O)N2C,0,13
332,13594,13594,13878,13878,"DRUGOTHER DRUG1 DRUGOTHER, like other DRUGOTHER, may inhibit the metabolism of DRUG2 and DRUGOTHER.",Theobromine,caffeine,False,Neg,0,CN1C=NC2=C1C(=O)NC(=O)N2C,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,1,11
333,13595,13595,13879,13879,"DRUGOTHER DRUG1 DRUGOTHER, like other DRUGOTHER, may inhibit the metabolism of DRUGOTHER and DRUG2.",Theobromine,theobromine,False,Neg,0,CN1C=NC2=C1C(=O)NC(=O)N2C,CN1C=NC2=C1C(=O)NC(=O)N2C,1,13
334,13598,13598,13882,13882,"DRUGOTHER DRUGOTHER DRUGOTHER, like other DRUGOTHER, may inhibit the metabolism of DRUG1 and DRUG2.",caffeine,theobromine,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CN1C=NC2=C1C(=O)NC(=O)N2C,11,13
335,13599,13599,13883,13883,"In some patients, this may lead to reduced clearance, prolongation of plasma half-life, and enhanced effects of DRUG1 and DRUG2.",caffeine,theobromine,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CN1C=NC2=C1C(=O)NC(=O)N2C,17,19
336,13601,13601,13885,13885,DRUG1: DRUGOTHER is a competitive inhibitor of the metabolism of DRUG2.,Theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,0,10
337,13604,13604,13888,13888,Serum DRUG1 concentrations increase when DRUGOTHER is initiated in a patient maintained on DRUG1.,theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,1,-1
338,13610,13610,13894,13894,"When initiating a multi-day course of DRUGOTHER in a patient maintained on DRUG1, the DRUG1 maintenance dose should be halved for the period of concurrent use of DRUGOTHER and monitoring of serum DRUG1 concentrations should be initiated as a guide to further dosage adjustments.",theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,12,-1
339,13612,13612,13896,13896,"When initiating a multi-day course of DRUGOTHER in a patient maintained on DRUG1, the DRUG1 maintenance dose should be halved for the period of concurrent use of DRUGOTHER and monitoring of serum DRUG1 concentrations should be initiated as a guide to further dosage adjustments.",theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,12,-1
340,13614,13614,13898,13898,"When initiating a multi-day course of DRUGOTHER in a patient maintained on DRUG1, the DRUG1 maintenance dose should be halved for the period of concurrent use of DRUGOTHER and monitoring of serum DRUG1 concentrations should be initiated as a guide to further dosage adjustments.",theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,12,-1
341,13626,13626,13910,13910,"Drugs Metabolized by Cytochrome P450 Enzymes The drug interaction study evaluating the effect of DRUGOTHER on DRUG1 indicates that DRUGOTHER inhibits DRUG1 metabolism, which is mediated by CYP1A2.",theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,16,-1
342,13670,13670,13957,13957,"In a study of 12 schizophrenic patients coadministered oral DRUG1 and DRUGOTHER, plasma DRUG1 levels were decreased by a mean of 70% and mean scores on the Brief Psychiatric Rating Scale were increased from baseline.",haloperidol,haloperidol,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,9,-1
343,13674,13674,13961,13961,"In 5 other schizophrenic patients treated with oral DRUG1 and DRUGOTHER, discontinuation of DRUGOTHER produced a mean 3.3-fold increase in DRUG1 concentrations.",haloperidol,haloperidol,False,Neg,0,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,8,-1
344,13934,13934,14223,14223,"DRUG1: Clinical studies, as well as random observations, have shown that DRUGOTHER can reduce the natriuretic effect of DRUG2 and DRUGOTHER in some patients.",Furosemide,furosemide,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,0,18
345,13935,13935,14224,14224,"DRUG1: Clinical studies, as well as random observations, have shown that DRUGOTHER can reduce the natriuretic effect of DRUGOTHER and DRUG2 in some patients.",Furosemide,thiazides,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,0,20
346,13938,13938,14227,14227,"DRUGOTHER: Clinical studies, as well as random observations, have shown that DRUGOTHER can reduce the natriuretic effect of DRUG1 and DRUG2 in some patients.",furosemide,thiazides,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,18,20
347,14012,14012,14306,14306,"Drugs that may alter DRUG1 plasma concentrations Drugs that may increase DRUG1 plasma concentrations: Caution is recommended when administering DRUGOTHER with inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER).",imatinib,imatinib,False,Neg,0,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,4,-1
348,14013,14013,14307,14307,"Drugs that may alter DRUG1 plasma concentrations Drugs that may increase DRUG1 plasma concentrations: Caution is recommended when administering DRUG2 with inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER).",imatinib,Gleevec,False,Neg,0,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,4,19
349,14018,14018,14312,14312,"Drugs that may alter DRUG1 plasma concentrations Drugs that may increase DRUG1 plasma concentrations: Caution is recommended when administering DRUG2 with inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER).",imatinib,Gleevec,False,Neg,0,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,4,19
350,14033,14033,14327,14327,There is a significant increase in exposure to DRUG1 when DRUG2 is coadministered with DRUGOTHER (CYP3A4 inhibitor).,imatinib,Gleevec,False,Neg,0,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,8,10
351,14036,14036,14330,14330,Drugs that may decrease DRUG1 plasma concentrations: Substances that are inducers of CYP3A4 activity may increase metabolism and decrease DRUG1 plasma concentrations.,imatinib,imatinib,False,Neg,0,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,4,-1
352,14049,14049,14343,14343,"Pretreatment of healthy volunteers with multiple doses of DRUGOTHER followed by a single dose of DRUG1, increased DRUG1 oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).",Gleevec,Gleevec,False,Neg,0,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,15,-1
353,14050,14050,14344,14344,"Drugs that may have their plasma concentration altered by DRUG1 DRUG1 increases the mean cmax and AUC of DRUGOTHER (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by DRUG1.",Gleevec,Gleevec,False,Neg,0,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,9,-1
354,14052,14052,14346,14346,"Drugs that may have their plasma concentration altered by DRUG1 DRUG1 increases the mean cmax and AUC of DRUGOTHER (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by DRUG1.",Gleevec,Gleevec,False,Neg,0,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,9,-1
355,14054,14054,14348,14348,"Drugs that may have their plasma concentration altered by DRUG1 DRUG1 increases the mean cmax and AUC of DRUGOTHER (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by DRUG1.",Gleevec,Gleevec,False,Neg,0,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,9,-1
356,14108,14108,14402,14402,"Ergot derivatives: DRUGOTHER, DRUG1, DRUGOTHER, methylDRUG1",ergonovine,methylergonovine,False,Neg,0,[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](CC)CO,[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](CC)CO,3,-1
357,14181,14181,14475,14475,Patients with Crohn s disease who received DRUG1 tended to experience fewer infusion reactions compared to patients on no DRUG1.,immunosuppressants,immunosuppressants,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,7,-1
358,14475,14475,14775,14775,DRUG1: DRUGOTHER may increase serum levels of DRUG2.,Phenytoin,phenytoin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,0,7
359,14481,14481,14781,14781,"Therophylline: A recent study has shown that concomitan administration of DRUGOTHER and DRUG1 may cause elevated plasma levels of DRUG1, and in some instances a slight decrease in the elimination of DRUGOTHER.",theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,12,-1
360,14484,14484,14784,14784,"Since the therapeutic range of DRUG1 is narrow DRUG1 serum levels should be monitored closely, and appropriate dosage adjustments of DRUG1 should be made.",theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,5,-1
361,14485,14485,14785,14785,"Since the therapeutic range of DRUG1 is narrow DRUG1 serum levels should be monitored closely, and appropriate dosage adjustments of DRUG1 should be made.",theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,5,-1
362,14486,14486,14786,14786,"Since the therapeutic range of DRUG1 is narrow DRUG1 serum levels should be monitored closely, and appropriate dosage adjustments of DRUG1 should be made.",theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,5,-1
363,14506,14506,14806,14806,DRUG1: DRUGOTHER has not been shown to alter the pharmacokinetics of DRUG2 in a study in seven healthy volunteers.,Phenytoin,phenytoin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,0,11
364,14516,14516,14816,14816,DRUG1: A study in normal healthy volunteers has shown that concomitant administration of DRUGOTHER  (DRUGOTHER) and DRUG2 does not result in altered pharmacoktnetics of either drug.,Hydrochlorothiazide,hydrochlorothiazide,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,0,17
365,14625,14625,14925,14925,"Although no studies have been conducted, concomitant administration of DRUGOTHER and DRUG1 may alter the metabolism of DRUG1;",phenytoin,phenytoin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,11,-1
366,14734,14734,15034,15034,"DRUGOTHER: DRUG1, given concomitantly with DRUGOTHER, produces a reduction in urinary potassium and chloride excretion compared to DRUG2 alone.",Hydrochlorothiazide,hydrochlorothiazide,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,1,17
367,14779,14779,15079,15079,"DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG1 The in vitro binding of DRUGOTHER to plasma proteins is only slightly reduced by DRUG2 (99.5% control vs 99.3%) when DRUGOTHER plasma concentrations reach 5 to10 m g/mL.",Heparin,ketorolac tromethamine,False,Neg,0,[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,4,19
368,14780,14780,15080,15080,"DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUG1 The in vitro binding of DRUGOTHER to plasma proteins is only slightly reduced by DRUG2 tromethamine (99.5% control vs 99.3%) when DRUG2 plasma concentrations reach 5 to10 m g/mL.",Heparin,ketorolac,False,Neg,0,[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,4,19
369,14783,14783,15083,15083,"DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER The in vitro binding of DRUGOTHER to plasma proteins is only slightly reduced by DRUG1 (99.5% control vs 99.3%) when DRUG2 plasma concentrations reach 5 to10 m g/mL.",ketorolac tromethamine,ketorolac,False,Neg,0,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,19,25
370,14787,14787,15087,15087,"In vitro studies indicate that, at therapeutic concentrations of DRUGOTHER (300 m g/mL), the binding of DRUG1 was reduced from approximately 99.2% to 97.5%, representing a potential twofold increase in unbound DRUG1 plasma levels.",ketorolac,ketorolac,False,Neg,0,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,16,-1
371,14815,14815,15115,15115,"Therapeutic concentrations of DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1 andtolbutamide did not alter DRUG2 protein binding.",phenytoin,ketorolac tromethamine,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,9,14
372,14820,14820,15120,15120,"Although these results do not indicate a significant interaction between DRUG1 and DRUGOTHER or DRUGOTHER, the administration of DRUG1 to patients taking DRUGOTHER should be done extremely cautiously, and patients should be closely monitored.",TORADOL,TORADOL,False,Neg,0,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,10,-1
373,14824,14824,15124,15124,DRUG1: DRUG2 IV/IM reduced the DRUGOTHER response to DRUGOTHER in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).,Furosemide,TORADOL,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,0,1
374,14826,14826,15126,15126,DRUG1: DRUGOTHER IV/IM reduced the DRUGOTHER response to DRUG2 in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).,Furosemide,furosemide,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,0,8
375,14828,14828,15128,15128,DRUGOTHER: DRUG1 IV/IM reduced the DRUGOTHER response to DRUG2 in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).,TORADOL,furosemide,True,effect,2,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,1,8
376,14835,14835,15135,15135,DRUGOTHER: Concomitant administration of DRUG1 ORAL and DRUGOTHER resulted in decreased clearance of DRUG2 and significant increases in DRUG2 plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.,TORADOL,ketorolac,False,Neg,0,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,4,13
377,14836,14836,15136,15136,DRUGOTHER: Concomitant administration of DRUG1 ORAL and DRUGOTHER resulted in decreased clearance of DRUG2 and significant increases in DRUG2 plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.,TORADOL,ketorolac,False,Neg,0,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,4,13
378,14839,14839,15139,15139,DRUGOTHER: Concomitant administration of DRUGOTHER ORAL and DRUGOTHER resulted in decreased clearance of DRUG1 and significant increases in DRUG1 plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.,ketorolac,ketorolac,False,Neg,0,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,13,-1
379,14841,14841,15141,15141,"The effect of DRUG1 on plasma DRUGOTHER has not been studied, but cases of increased DRUGOTHER plasma levels during DRUG1 therapy have been reported.",TORADOL,TORADOL,False,Neg,0,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,3,-1
380,14849,14849,15149,15149,"DRUGOTHER: Sporadic cases of seizures have been reported during concomitant use of DRUG1 and DRUGOTHER (DRUG2, DRUGOTHER).",TORADOL,phenytoin,True,effect,2,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,12,15
381,14969,14969,15277,15277,"DRUGOTHER such as DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUGOTHER), DRUGOTHER (e.g., DRUG1), and DRUGOTHER (e.g., DRUGOTHER): Using these medicines with DRUG2 may increase the chance of side effects.",Eldepryl,L-tryptophan,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,N[C@@H](CC1=CNC2=CC=CC=C12)C(O)=O,14,23
382,15061,15061,15370,15370,"When DRUGOTHER was administered concomitantly with DRUG1 (CYP1A2, CYP3A), a minor increase (10%) in the clearance of DRUG1 was seen.",theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,6,-1
383,15153,15153,15476,15476,Drug-Drug Interactions Between DRUGOTHER  And Other DRUGOTHER (DRUGOTHER) DRUG1 DRUGOTHER  (3000 mg daily) had no effect on the pharmacokinetic disposition of DRUG2 in patients with refractory epilepsy.,Phenytoin,phenytoin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,9,23
384,15174,15174,15497,15497,"Potential drug interactions between DRUGOTHER  and other DRUGOTHER (DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER and DRUGOTHER) were also assessed by evaluating the serum concentrations of DRUGOTHER and these DRUGOTHER during placebo-controlled clinical studies.",gabapentin,phenytoin,False,Neg,0,NCC1(CC(O)=O)CCCCC1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,10,13
385,15252,15252,15579,15579,"However, the systemic administration of some DRUGOTHER has been shown to elevate plasma concentrations of DRUG1, interfere with the metabolism of DRUG2, and enhance the effects of the oral DRUGOTHER DRUGOTHER and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic DRUGOTHER concomitantly.",theophylline,caffeine,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,15,21
386,15337,15337,15672,15672,"Interactions with DRUGOTHER: DRUGOTHER (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUG1) should NOT be administered to a patient who has received or is receiving a course of therapy with a DRUGOTHER such as DRUG2.",buprenorphine,Levo-Dromoran,True,advise,1,C[C@]([C@H]1C[C@@]23CC[C@@]1([C@H]4[C@@]25CCN([C@@H]3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)(C(C)(C)C)O,[H][C@@]12CCCC[C@@]11CCN(C)[C@@H]2CC2=C1C=C(O)C=C2,10,33
387,15458,15458,15806,15806,"Binding to Serum Proteins: The following agents may either inhibit DRUGOTHER binding to serum proteins or alter the concentrations of serum binding proteins: DRUGOTHER and related DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER.",furosemide,phenytoin,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,33,40
388,15935,15935,16283,16283,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER.",nitroprusside,phenytoin,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,69,71
389,15939,15939,16287,16287,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER.",nitroprusside,sulfonamides,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,69,75
390,15950,15950,16298,16298,"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and related anabolic hormones, complex anions (DRUGOTHER, DRUGOTHER, DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER agonists, DRUGOTHER, DRUGOTHER, DRUGOTHER, hepatic enzyme inducers, DRUGOTHER, iodinated cholestographic agents, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER.",phenytoin,sulfonamides,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,71,75
391,15978,15978,16326,16326,DRUG1: DRUG1 clearance may decrease in hypothyroid patients and return toward normal when a euthyroid state is achieved.,Theophylline,Theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,0,-1
392,15994,15994,16343,16343,"DRUGOTHER:Some individuals receiving DRUG1 may experience a reversible enhancement of the pressor response to indirect-acting DRUGOTHER, DRUG2 or DRUGOTHER.",ZYVOX,vasopressor,True,effect,2,CC(=O)NC[C@H]1CN(C(=O)O1)C1=CC(F)=C(C=C1)N1CCOCC1,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,3,16
393,16006,16006,16355,16355,"Spontaneous reports of serotonin syndrome associated with co-administration of DRUG1 and DRUGOTHER, including DRUGOTHER such as DRUG2 (DRUGOTHER), have been reported.",ZYVOX,selective serotonin reuptake inhibitors,True,effect,2,CC(=O)NC[C@H]1CN(C(=O)O1)C1=CC(F)=C(C=C1)N1CCOCC1,NCCC1=CNC2=CC=C(O)C=C12,9,16
394,16089,16089,16438,16438,DRUG1: DRUGOTHER may delay intestinal absorption of DRUG2.,Ethosuximide,ethosuximide,False,Neg,0,CCC1(C)CC(=O)NC1=O,CCC1(C)CC(=O)NC1=O,0,7
395,16091,16091,16440,16440,"DRUG1: DRUG1 blocks dopamine receptors, thus inhibiting the central stimulant effects of DRUGOTHER.",Haloperidol,Haloperidol,False,Neg,0,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1,0,-1
396,16098,16098,16447,16447,DRUG1: DRUGOTHER potentiate the analgesic effect of DRUG2.,Meperidine,meperidine,False,Neg,0,CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,0,7
397,16108,16108,16459,16459,DRUG1: DRUGOTHER may delay intestinal absorption of DRUG2;,Phenytoin,phenytoin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,0,7
398,16145,16145,16496,16496,"DRUG1: In three pharmacokinetic studies including 46 normal, healthy subjects, DRUG2 clearance and concentration were not significantly altered by the addition of DRUGOTHER.",Theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,0,10
399,16149,16149,16500,16500,"In clinical studies where patients were on chronic DRUG1 therapy, DRUGOTHER had no measurable effect on the mean distribution of DRUG1 concentrations or the mean estimates of DRUG1 clearance.",theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,8,-1
400,16150,16150,16501,16501,"In clinical studies where patients were on chronic DRUG1 therapy, DRUGOTHER had no measurable effect on the mean distribution of DRUG1 concentrations or the mean estimates of DRUG1 clearance.",theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,8,-1
401,16153,16153,16504,16504,"In clinical studies where patients were on chronic DRUG1 therapy, DRUGOTHER had no measurable effect on the mean distribution of DRUG1 concentrations or the mean estimates of DRUG1 clearance.",theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,8,-1
402,16168,16168,16519,16519,"DRUG1: Two hundred mg of DRUG2 (equivalent to 1 to 3 cups of American coffee) was administered to 16 normal, healthy volunteers who had achieved steady-state blood concentrations of DRUGOTHER after being dosed at 400 mg qd.",Caffeine,caffeine,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,0,5
403,16171,16171,16522,16522,"This did not result in any statistically or clinically relevant changes in the pharmacokinetic parameters of either DRUG1 or its major metabolite, DRUG2.",caffeine,paraxanthine,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,O=C1NC2=C(NC=N2)C(=O)N1,17,22
404,16172,16172,16523,16523,"Other DRUGOTHER have demonstrated moderate to marked interference with the metabolism of DRUG1, resulting in a reduced clearance, a prolongation of plasma half-life, and an increase in symptoms that accompany high levels of DRUG1.",caffeine,caffeine,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,12,-1
405,16185,16185,16536,16536,"DRUG1: No significant differences were observed in mean DRUG2 AUC, C max , C min or T max (although C max increased by 11%) when extended DRUG2 sodium capsules (100 mg tid) were coadministered with DRUGOTHER (400 mg qd) for five days in 15 healthy males.",Phenytoin,phenytoin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,0,8
406,16186,16186,16537,16537,"DRUG1: No significant differences were observed in mean DRUGOTHER AUC, C max , C min or T max (although C max increased by 11%) when extended DRUG2 capsules (100 mg tid) were coadministered with DRUGOTHER (400 mg qd) for five days in 15 healthy males.",Phenytoin,phenytoin sodium,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,0,26
407,16188,16188,16539,16539,"DRUGOTHER: No significant differences were observed in mean DRUG1 AUC, C max , C min or T max (although C max increased by 11%) when extended DRUG1 sodium capsules (100 mg tid) were coadministered with DRUGOTHER (400 mg qd) for five days in 15 healthy males.",phenytoin,phenytoin sodium,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,8,-1
408,16361,16361,16719,16719,"DRUG1: Clinical studies, as well as post-marketing observations, have shown that DRUGOTHER can reduce the natriuretic effect of DRUG2 and DRUGOTHER in some patients.",Furosemide,furosemide,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,0,18
409,16362,16362,16720,16720,"DRUG1: Clinical studies, as well as post-marketing observations, have shown that DRUGOTHER can reduce the natriuretic effect of DRUGOTHER and DRUG2 in some patients.",Furosemide,thiazides,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,0,20
410,16363,16363,16721,16721,"DRUGOTHER: Clinical studies, as well as post-marketing observations, have shown that DRUGOTHER can reduce the natriuretic effect of DRUG1 and DRUG2 in some patients.",furosemide,thiazides,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,18,20
411,16446,16446,16828,16828,DRUG1-DRUG1 may decrease the absorption of DRUGOTHER.,Orlistat,Orlistat,False,Neg,0,CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,0,-1
412,16472,16472,16854,16854,There have been reports of DRUG1-related side effects in patients on concomitant therapy with DRUGOTHER and DRUG1.,theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,5,-1
413,16473,16473,16855,16855,"Therefore, monitoring of DRUG1 plasma levels should be considered and dosage of DRUG1 adjusted, as required.",theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,3,-1
414,16530,16530,16918,16918,"In vitro displacement studies with highly protein-bound drugs such as DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER showed no influence on the extent of DRUGOTHER protein binding.",furosemide,captopril,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,10,12
415,16532,16532,16920,16920,"In vitro displacement studies with highly protein-bound drugs such as DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER showed no influence on the extent of DRUGOTHER protein binding.",furosemide,pravastatin,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,10,14
416,16535,16535,16923,16923,"In vitro displacement studies with highly protein-bound drugs such as DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER showed no influence on the extent of DRUGOTHER protein binding.",furosemide,phenytoin,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,10,17
417,16551,16551,16939,16939,"In vitro displacement studies with highly protein-bound drugs such as DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER showed no influence on the extent of DRUGOTHER protein binding.",captopril,pravastatin,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,12,14
418,16554,16554,16942,16942,"In vitro displacement studies with highly protein-bound drugs such as DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER showed no influence on the extent of DRUGOTHER protein binding.",captopril,phenytoin,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,12,17
419,16569,16569,16957,16957,"In vitro displacement studies with highly protein-bound drugs such as DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, and DRUGOTHER showed no influence on the extent of DRUGOTHER protein binding.",pravastatin,phenytoin,False,Neg,0,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,14,17
420,16754,16754,17143,17143,DRUG1: Coadministration of DRUG2 with DRUGOTHER resulted in a 152% increase in DRUGOTHER plasma AUC and very little change in DRUG2 plasma A.C.,Ritonavir,ritonavir,False,Neg,0,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,0,3
421,16757,16757,17146,17146,DRUG1: Coadministration of DRUG2 with DRUGOTHER resulted in a 152% increase in DRUGOTHER plasma AUC and very little change in DRUG2 plasma A.C.,Ritonavir,ritonavir,False,Neg,0,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,0,3
422,16760,16760,17149,17149,DRUGOTHER: Coadministration of DRUG1 with DRUGOTHER resulted in a 152% increase in DRUGOTHER plasma AUC and very little change in DRUG1 plasma A.C.,ritonavir,ritonavir,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,3,-1
423,16764,16764,17153,17153,DRUG1: Coadministration of DRUG2 (using an experimental soft-gelatin capsule formulation of DRUG2 1200mg) with DRUGOTHER resulted in an 18% increase in DRUGOTHER plasma AUC and a 4-fold increase in DRUG2 plasma A.C.,Saquinavir,saquinavir,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,0,3
424,16765,16765,17154,17154,DRUG1: Coadministration of DRUG2 (using an experimental soft-gelatin capsule formulation of DRUG2 1200mg) with DRUGOTHER resulted in an 18% increase in DRUGOTHER plasma AUC and a 4-fold increase in DRUG2 plasma A.C.,Saquinavir,saquinavir,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,0,3
425,16768,16768,17157,17157,DRUG1: Coadministration of DRUG2 (using an experimental soft-gelatin capsule formulation of DRUG2 1200mg) with DRUGOTHER resulted in an 18% increase in DRUGOTHER plasma AUC and a 4-fold increase in DRUG2 plasma A.C.,Saquinavir,saquinavir,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,0,3
426,16769,16769,17158,17158,DRUGOTHER: Coadministration of DRUG1 (using an experimental soft-gelatin capsule formulation of DRUG1 1200mg) with DRUGOTHER resulted in an 18% increase in DRUGOTHER plasma AUC and a 4-fold increase in DRUG1 plasma A.C.,saquinavir,saquinavir,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,3,-1
427,16772,16772,17161,17161,DRUGOTHER: Coadministration of DRUG1 (using an experimental soft-gelatin capsule formulation of DRUG1 1200mg) with DRUGOTHER resulted in an 18% increase in DRUGOTHER plasma AUC and a 4-fold increase in DRUG1 plasma A.C.,saquinavir,saquinavir,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,3,-1
428,16775,16775,17164,17164,DRUGOTHER: Coadministration of DRUG1 (using an experimental soft-gelatin capsule formulation of DRUG1 1200mg) with DRUGOTHER resulted in an 18% increase in DRUGOTHER plasma AUC and a 4-fold increase in DRUG1 plasma A.C.,saquinavir,saquinavir,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,3,-1
429,16961,16961,17359,17359,"Consequently, drugs with a low therapeutic margin, such as DRUGOTHER, DRUG1, and DRUG2, could have a delayed elimination and increases in their serum half-life leading to a toxic level.",phenytoin,theophylline,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CN1C2=C(C(=O)N(C1=O)C)NC=N2,10,12
430,17016,17016,17419,17419,"No interactions have been observed between DRUGOTHER and DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER.",theophylline,phenytoin,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,8,12
431,17042,17042,17445,17445,There have been reports of DRUG1-related side effects in patients on concomitant therapy with DRUGOTHER and DRUG1.,theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,5,-1
432,17044,17044,17447,17447,"Therefore, monitoring of DRUG1 plasma levels should be considered and dosage of DRUG1 adjusted as required.",theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,3,-1
433,17090,17090,17493,17493,"A similar association, though less marked, has been suggested with DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, and possibly with DRUGOTHER and DRUGOTHER 72.",phenytoin sodium,topiramate,False,Neg,0,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,12,15
434,17202,17202,17605,17605,"Potential interactions between DRUGOTHER, a substrate of CYP3A4, and DRUGOTHER (DRUG1, DRUG2, DRUGOTHER, and DRUGOTHER), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.",ritonavir,saquinavir,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,10,11
435,17224,17224,17627,17627,DRUG1 serum levels should be monitored and appropriate dose adjustments considered for patients given both DRUG2 and DRUGOTHER.,Theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,0,15
436,17273,17273,17686,17686,"DRUG1: Clinical studies, as well as post-marketing observations, have shown that DRUGOTHER can reduce the natriuretic effect of DRUG2 and DRUGOTHER in some patients.",Furosemide,furosemide,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,0,18
437,17274,17274,17687,17687,"DRUG1: Clinical studies, as well as post-marketing observations, have shown that DRUGOTHER can reduce the natriuretic effect of DRUGOTHER and DRUG2 in some patients.",Furosemide,thiazides,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,0,20
438,17275,17275,17688,17688,"DRUGOTHER: Clinical studies, as well as post-marketing observations, have shown that DRUGOTHER can reduce the natriuretic effect of DRUG1 and DRUG2 in some patients.",furosemide,thiazides,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,18,20
439,17319,17319,17732,17732,"DRUG1 DRUGOTHER 12.5, 25, and 50 mg administered once daily for 7 days increased plasma DRUG2 concentrations (AUC(0- )) by 38 to 60% in healthy subjects administered a single 300-mg dose of DRUG2.",Theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,0,15
440,17320,17320,17733,17733,"DRUG1 DRUGOTHER 12.5, 25, and 50 mg administered once daily for 7 days increased plasma DRUG2 concentrations (AUC(0- )) by 38 to 60% in healthy subjects administered a single 300-mg dose of DRUG2.",Theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,0,15
441,17323,17323,17736,17736,"DRUGOTHER DRUGOTHER 12.5, 25, and 50 mg administered once daily for 7 days increased plasma DRUG1 concentrations (AUC(0- )) by 38 to 60% in healthy subjects administered a single 300-mg dose of DRUG1.",theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,15,-1
442,17325,17325,17738,17738,Adequate monitoring of DRUG1 plasma concentrations should be considered when therapy with DRUGOTHER is initiated or changed in patients receiving DRUG1.,theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,3,-1
443,17333,17333,17748,17748,Several drug interaction studies have been completed with both DRUG1 and DRUG2.,INVIRASE,FORTOVASE,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,9,11
444,17334,17334,17749,17749,Observations from drug interaction studies with DRUG1 may not be predictive for DRUG2.,FORTOVASE,INVIRASE,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,6,12
445,17335,17335,17750,17750,"Because DRUG1 is coadministered, prescribers should also refer to the prescribing information for DRUG1 regarding drug interactions associated with this agent.",ritonavir,ritonavir,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1,-1
446,17336,17336,17751,17751,Additional drugs that are not recommended for coadministration with DRUG1 and DRUG2 are included below.,INVIRASE,ritonavir,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,9,11
447,17337,17337,17752,17752,Drugs That Should Not Be Coadministered With DRUG1/DRUG2,INVIRASE,Ritonavir,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,7,7
448,17355,17355,17771,17771,"DRUGOTHER: DRUGOTHER, DRUG1, DRUGOTHER, methylDRUG1 CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute DRUGOTHER toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.",ergonovine,methylergonovine,False,Neg,0,[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](CC)CO,[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](CC)CO,2,-1
449,17365,17365,17784,17784,DRUGOTHER: DRUGOTHER CONTRAINDICATED since the coadministration of this product with DRUG1 in an DRUGOTHER regimen reduces the plasma concentrations of DRUG1.,saquinavir,saquinavir,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,10,-1
450,17367,17367,17786,17786,Garlic Capsules Garlic capsules should not be used while taking DRUG1 (DRUG2) as the sole DRUGOTHER due to the risk of decreased DRUG1 plasma concentrations.,saquinavir,FORTOVASE,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,10,11
451,17368,17368,17787,17787,Garlic Capsules Garlic capsules should not be used while taking DRUG1 (DRUGOTHER) as the sole DRUGOTHER due to the risk of decreased DRUG1 plasma concentrations.,saquinavir,saquinavir,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,10,-1
452,17369,17369,17788,17788,Garlic Capsules Garlic capsules should not be used while taking DRUG2 (DRUG1) as the sole DRUGOTHER due to the risk of decreased DRUG2 plasma concentrations.,FORTOVASE,saquinavir,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,11,10
453,17370,17370,17789,17789,No data are available for the coadministration of DRUG1/DRUG2 or DRUGOTHER/DRUG2 and garlic capsules.,INVIRASE,ritonavir,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,8,8
454,17371,17371,17790,17790,No data are available for the coadministration of DRUG1/DRUGOTHER or DRUG2/DRUGOTHER and garlic capsules.,INVIRASE,FORTOVASE,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,8,10
455,17372,17372,17791,17791,No data are available for the coadministration of DRUG1/DRUG2 or DRUGOTHER/DRUG2 and garlic capsules.,INVIRASE,ritonavir,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,8,8
456,17373,17373,17792,17792,No data are available for the coadministration of DRUGOTHER/DRUG1 or DRUG2/DRUG1 and garlic capsules.,ritonavir,FORTOVASE,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,8,10
457,17374,17374,17793,17793,No data are available for the coadministration of DRUGOTHER/DRUG1 or DRUGOTHER/DRUG1 and garlic capsules.,ritonavir,ritonavir,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,8,-1
458,17375,17375,17794,17794,No data are available for the coadministration of DRUGOTHER/DRUG2 or DRUG1/DRUG2 and garlic capsules.,FORTOVASE,ritonavir,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,10,8
459,17473,17473,17892,17892,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, alDRUG1, DRUGOTHER, and DRUGOTHER) may have elevated plasma concentrations when coadministered with DRUGOTHER;",fentanyl,alfentanyl,False,Neg,0,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,29,-1
460,17476,17476,17895,17895,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, alDRUG1, DRUGOTHER, and DRUGOTHER) may have elevated plasma concentrations when coadministered with DRUG2;",fentanyl,saquinavir,True,mechanism,4,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,29,42
461,17479,17479,17898,17898,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, and DRUGOTHER) may have elevated plasma concentrations when coadministered with DRUG2;",alfentanyl,saquinavir,True,mechanism,4,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,30,42
462,17483,17483,17902,17902,"Since DRUG1 is coadministered with DRUG2, the DRUG2 label should be reviewed for additional drugs that should not be coadministered.",INVIRASE,ritonavir,True,advise,1,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1,5
463,17484,17484,17903,17903,"Since DRUG1 is coadministered with DRUG2, the DRUG2 label should be reviewed for additional drugs that should not be coadministered.",INVIRASE,ritonavir,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,1,5
464,17485,17485,17904,17904,"Since DRUGOTHER is coadministered with DRUG1, the DRUG1 label should be reviewed for additional drugs that should not be coadministered.",ritonavir,ritonavir,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,5,-1
465,17492,17492,17911,17911,"Coadministration with compounds that are potent inducers of CYP3A4 (eg, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER) may result in decreased plasma levels of DRUG2.",phenytoin,saquinavir,True,mechanism,4,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,11,21
466,17503,17503,17923,17923,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUG1 [e.g., DRUG2], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",oxandrolone,Anavar,False,Neg,0,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(COC(=O)C4)C,[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)OC[C@]12C,5,7
467,17650,17650,18072,18072,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUG1], DRUG2 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",Prolixin,mesoridazine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CN1CCCCC1CCN1C2=C(SC3=C1C=C(C=C3)S(C)=O)C=CC=C2,10,11
468,17660,17660,18082,18082,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUG1], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG2 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",Prolixin,thioridazine,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,10,26
469,17676,17676,18098,18098,"- DRUGOTHER (DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG1 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], DRUG2 [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER], trifluDRUGOTHER [e.g., DRUGOTHER], DRUGOTHER [e.g., DRUGOTHER]) or",mesoridazine,thioridazine,False,Neg,0,CN1CCCCC1CCN1C2=C(SC3=C1C=C(C=C3)S(C)=O)C=CC=C2,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,11,26
470,17834,17834,18257,18257," DRUG1 (e.g., DRUG2) use of DRUGOTHER with DRUGOTHER may increase The chance of side effects affecting The liver and/or The side effects of DRUGOTHER",Phenytoin,Dilantin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,1,3
471,17835,17835,18258,18258," DRUG1 (e.g., DRUGOTHER) use of DRUG2 with DRUGOTHER may increase The chance of side effects affecting The liver and/or The side effects of DRUG2",Phenytoin,phenytoin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,1,6
472,17837,17837,18260,18260," DRUG1 (e.g., DRUGOTHER) use of DRUG2 with DRUGOTHER may increase The chance of side effects affecting The liver and/or The side effects of DRUG2",Phenytoin,phenytoin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,1,6
473,17838,17838,18261,18261," DRUGOTHER (e.g., DRUG1) use of DRUG2 with DRUGOTHER may increase The chance of side effects affecting The liver and/or The side effects of DRUG2",Dilantin,phenytoin,False,Neg,0,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,3,6
474,17840,17840,18263,18263," DRUGOTHER (e.g., DRUG1) use of DRUG2 with DRUGOTHER may increase The chance of side effects affecting The liver and/or The side effects of DRUG2",Dilantin,phenytoin,False,Neg,0,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,3,6
475,17842,17842,18265,18265," DRUGOTHER (e.g., DRUGOTHER) use of DRUG1 with DRUGOTHER may increase The chance of side effects affecting The liver and/or The side effects of DRUG1",phenytoin,phenytoin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,6,-1
476,17853,17853,18276,18276,Effects of DRUGOTHER on other Antiepilepsy Drugs (DRUGOTHER) : DRUG1: DRUGOTHER had no effect on the steady-state plasma concentrations of DRUG2 in patients with epilepsy.,Phenytoin,phenytoin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,9,20
477,17879,17879,18302,18302,DRUG1: Population pharmacokinetic analyses indicate that DRUGOTHER clearance is 60% greater in patients taking DRUG2 with or without other enzyme- inducing DRUGOTHER.,Phenytoin,phenytoin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,0,14
478,17912,17912,18335,18335,DRUG1: A single 10 mg dose of DRUGOTHER did not affect the pharmacokinetics of DRUG2 at steady state.,Theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,0,14
479,17959,17959,18382,18382,"DRUG1: Clinical studies, as well as post-marketing observations, have shown that DRUGOTHER can reduce the natriuretic effect of DRUG2 and DRUGOTHER in some patients.",Furosemide,furosemide,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,0,18
480,17960,17960,18383,18383,"DRUG1: Clinical studies, as well as post-marketing observations, have shown that DRUGOTHER can reduce the natriuretic effect of DRUGOTHER and DRUG2 in some patients.",Furosemide,thiazides,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,0,20
481,17961,17961,18384,18384,"DRUGOTHER: Clinical studies, as well as post-marketing observations, have shown that DRUGOTHER can reduce the natriuretic effect of DRUG1 and DRUG2 in some patients.",furosemide,thiazides,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,18,20
482,17966,17966,18389,18389,DRUGOTHER (DRUG1): Steady state plasma exposure (AUC) of DRUGOTHER (40 mg BID for 12 days) was decreased by 27% when co-administered with multiple doses (300 mg QD for 12 days) of DRUG2 (a CYP 3A4 inducer).,Phenytoin,phenytoin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,1,31
483,17970,17970,18393,18393,DRUG1: DRUG1 is primarily metabolized by CYP 2D6 and to a lesser extent by 3A4.,Dextromethorphan,Dextromethorphan,False,Neg,0,[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C,[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C,0,-1
484,18155,18155,18578,18578,"DRUG1 and DRUGOTHER: Upon concomitant administration of 5 mg of DRUGOTHER with 600 mg BID DRUG2, the Cmax and AUC of DRUG2 were reduced by approximately 20%.",Ritonavir,ritonavir,False,Neg,0,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,0,15
485,18156,18156,18579,18579,"DRUG1 and DRUGOTHER: Upon concomitant administration of 5 mg of DRUGOTHER with 600 mg BID DRUG2, the Cmax and AUC of DRUG2 were reduced by approximately 20%.",Ritonavir,ritonavir,False,Neg,0,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,0,15
486,18162,18162,18585,18585,"DRUGOTHER and DRUGOTHER: Upon concomitant administration of 5 mg of DRUGOTHER with 600 mg BID DRUG1, the Cmax and AUC of DRUG1 were reduced by approximately 20%.",ritonavir,ritonavir,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,15,-1
487,18204,18204,18627,18627,"DRUG1: The combination of DRUGOTHER, DRUG2, and DRUGOTHER has been studied (as triple combination) in adults.",Saquinavir,saquinavir,False,Neg,0,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,0,5
488,18290,18290,18713,18713,"Drugs that have been associated with peripheral neuropathy include DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, and DRUGOTHER.",hydralazine,phenytoin,False,Neg,0,C1=CC=C2C(=C1)C=NN=C2NN,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,17,22
489,18622,18622,19073,19073,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the DRUG1, DRUGOTHER, DRUGOTHER, and DRUGOTHER (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., DRUG1, DRUGOTHER, DRUGOTHER, and DRUGOTHER with DRUGOTHER plus DRUGOTHER) without receiving DRUGOTHER therapy. ",cyclophosphamide,cyclophosphamide,False,Neg,0,ClCCN(CCCl)P1(=O)NCCCO1,ClCCN(CCCl)P1(=O)NCCCO1,36,-1
490,18802,18802,19268,19268,"RESULTS: The geometric mean (90% confidence interval) whole blood DRUG1 area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with DRUGOTHER coadministration, whereas the mean elimination half-life of DRUG1 decreased slightly, from 79 to 67 hours. ",sirolimus,sirolimus,False,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,9,-1
491,18804,18804,19270,19270,"Apparent oral clearance and volume of distribution of DRUG1 decreased with 38% and 45%, respectively, when DRUG1 was given with DRUGOTHER. ",sirolimus,sirolimus,False,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,8,-1
492,18819,18819,19285,19285,"CONCLUSIONS: Single-dose DRUGOTHER coadministration leads to higher DRUG1 exposure, presumably by inhibition of the first-pass metabolism of DRUG1. ",sirolimus,sirolimus,False,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,7,-1
493,18821,18821,19287,19287,"Because of the pronounced intersubject variability in the extent of the DRUG1-DRUGOTHER interaction, whole blood DRUG1 concentrations should be monitored closely in patients treated with the two drugs.",sirolimus,sirolimus,False,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,11,-1
494,18899,18899,19365,19365,"DRUGOTHER/DRUG1, DRUGOTHER/DRUGOTHER, DRUGOTHER/DRUGOTHER, DRUGOTHER/DRUGOTHER, DRUGOTHER/DRUGOTHER, DRUG1/DRUGOTHER, and DRUGOTHER/DRUGOTHER. ",theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,0,-1
495,18973,18973,19439,19439,"The serum concentration of DRUG1 increased dramatically from 16.6 to 49.1 microg/mL when DRUGOTHER was coadministered, although the daily dosage of DRUG1 and other DRUGOTHER had not changed. ",phenytoin,phenytoin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,4,-1
496,18978,18978,19444,19444,"During DRUG1 and fluvoxamine treatment, ataxia, a typical side effect of DRUG1, was observed. ",phenytoin,phenytoin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,1,-1
497,19207,19207,19692,19692,"DRUG1: mammalian target of DRUG2 inhibitor to prevent kidney rejection.
",Sirolimus,rapamycin,False,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC,0,4
498,19208,19208,19693,19693,"DRUG1 works differently from the DRUG2 currently available, and except for increased lipid levels, the adverse reaction profile of DRUGOTHER does not appear to overlap to any great extent with that associated with DRUGOTHER or DRUGOTHER. ",Sirolimus,immunosuppressants,False,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,0,5
499,19209,19209,19694,19694,"DRUG1 works differently from the DRUGOTHER currently available, and except for increased lipid levels, the adverse reaction profile of DRUG2 does not appear to overlap to any great extent with that associated with DRUGOTHER or DRUGOTHER. ",Sirolimus,sirolimus,False,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,0,19
500,19212,19212,19697,19697,"DRUGOTHER works differently from the DRUG1 currently available, and except for increased lipid levels, the adverse reaction profile of DRUG2 does not appear to overlap to any great extent with that associated with DRUGOTHER or DRUGOTHER. ",immunosuppressants,sirolimus,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,5,19
501,19382,19382,19878,19878,"Because the DRUGOTHER DRUG1 is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral DRUG1, either alone or in combination with the chemosensitizer DRUGOTHER. ",CCNU,CCNU,False,Neg,0,ClCCN(N=O)C(=O)NC1CCCCC1,ClCCN(N=O)C(=O)NC1CCCCC1,3,-1
502,19388,19388,19884,19884,"Enhanced DRUG1 clearance secondary to DRUG2 therapy.
",theophylline,phenytoin,True,mechanism,4,CN1C2=C(C(=O)N(C1=O)C)NC=N2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,1,5
503,19389,19389,19885,19885,This report describes two cases in which DRUG1 clearance accelerated markedly with concomitant DRUG2 administration. ,theophylline,phenytoin,True,mechanism,4,CN1C2=C(C(=O)N(C1=O)C)NC=N2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,7,13
504,19390,19390,19886,19886,"With combined use, clinicians should be aware, when DRUG1 is added, of the potential for reexacerbation of pulmonary symptomatology due to lowered serum DRUG2 concentrations.",phenytoin,theophylline,True,effect,2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CN1C2=C(C(=O)N(C1=O)C)NC=N2,8,23
505,19397,19397,19894,19894,"Since DRUG1 is frequently co-administered with DRUGOTHER, it is of clinical interest to study the effect of DRUG1 on the hepatotoxicity of DRUGOTHER. ",caffeine,caffeine,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,1,-1
506,19480,19480,19987,19987,"This article looks at five commonly used DRUG1 in turn (DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. ",immunosuppressive drugs,cyclophosphamide,False,Neg,0,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,ClCCN(CCCl)P1(=O)NCCCO1,7,14
507,19504,19504,20011,20011,"We investigated the effects of adenosine receptor antagonists, DRUG1, DRUG2, 8-phenylDRUG2, and DRUGOTHER (DRUGOTHER), in a light/dark test in mice. ",caffeine,theophylline,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CN1C2=C(C(=O)N(C1=O)C)NC=N2,8,9
508,19505,19505,20012,20012,"We investigated the effects of adenosine receptor antagonists, DRUG1, DRUGOTHER, DRUG2, and DRUGOTHER (DRUGOTHER), in a light/dark test in mice. ",caffeine,8-phenyltheophylline,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,CN1C2=C(NC=N2)C(=O)N(C)C1=O,8,10
509,19506,19506,20014,20014,"We investigated the effects of adenosine receptor antagonists, DRUGOTHER, DRUG1, 8-phenylDRUG1, and DRUGOTHER (DRUGOTHER), in a light/dark test in mice. ",theophylline,8-phenyltheophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(NC=N2)C(=O)N(C)C1=O,9,-1
510,19593,19593,20115,20115,"These are described in greater detail below:  Oral DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER,  Oral DRUGOTHER: Clinically significant hypoglycemia may be precipitated by the use of DRUGOTHER with oral DRUGOTHER; ",Phenytoin,Theophylline,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CN1C2=C(C(=O)N(C1=O)C)NC=N2,11,14
511,19658,19658,20180,20180,DRUG1: DRUGOTHER increases the plasma concentrations of DRUG2. ,Phenytoin,phenytoin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,0,7
512,19661,19661,20183,20183,Careful monitoring of DRUG1 concentrations in patients receiving DRUGOTHER and DRUG1 is recommended. ,phenytoin,phenytoin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,3,-1
513,19674,19674,20196,20196,DRUG1: DRUGOTHER increases the serum concentrations of DRUG2. ,Theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,0,7
514,19677,19677,20199,20199,Careful monitoring of serum DRUG1 concentrations in patients receiving DRUGOTHER and DRUG1 is recommended. ,theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,4,-1
515,19770,19770,20292,20292,DRUGOTHER may reduce the effects of DRUG1 (DRUG2). ,guanethidine,Ismelin,False,Neg,0,C1CCCN(CCC1)CCN=C(N)N,C1CCCN(CCC1)CCN=C(N)N,6,7
516,19841,19841,20363,20363,"Before taking this medication, tell your doctor if you are taking a DRUGOTHER such as DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUG1 (DRUG2), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), DRUGOTHER (DRUGOTHER), or DRUGOTHER (DRUGOTHER). ",doxepin,Sinequan,False,Neg,0,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31,19,20
517,19917,19917,20450,20450,"DRUG1 may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",Melatonin,melatonin,False,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,0,13
518,19919,19919,20452,20452,"DRUG1 may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",Melatonin,melatonin,False,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,0,13
519,19920,19920,20453,20453,"DRUG1 may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",Melatonin,melatonin,False,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,0,13
520,19923,19923,20456,20456,"DRUG1 may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",Melatonin,melatonin,False,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,0,13
521,19926,19926,20459,20459,"DRUG1 may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG2 levels), DRUGOTHER (bioavailability of oral DRUG2 is increased with coadministration), DRUGOTHER (may decrease DRUG2 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG2 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG2 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",Melatonin,melatonin,False,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,0,13
522,19942,19942,20475,20475,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",melatonin,melatonin,False,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,13,-1
523,19943,19943,20476,20476,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",melatonin,melatonin,False,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,13,-1
524,19946,19946,20479,20479,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",melatonin,melatonin,False,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,13,-1
525,19949,19949,20482,20482,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",melatonin,melatonin,False,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,13,-1
526,19962,19962,20495,20495,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",melatonin,melatonin,False,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,13,-1
527,19965,19965,20498,20498,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",melatonin,melatonin,False,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,13,-1
528,19968,19968,20501,20501,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",melatonin,melatonin,False,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,13,-1
529,19973,19973,20506,20506,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",melatonin,melatonin,False,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,13,-1
530,19976,19976,20509,20509,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",melatonin,melatonin,False,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,13,-1
531,19994,19994,20527,20527,"DRUGOTHER may interact with the following drugs: DRUGOTHER and other DRUGOTHER (may lower DRUG1 levels), DRUGOTHER (bioavailability of oral DRUG1 is increased with coadministration), DRUGOTHER (may decrease DRUG1 levels), DRUGOTHER (reports of psychotic episodes when coadministered), DRUGOTHER (coadministration of DRUG1 with DRUGOTHER can inhibit ovarian function in women), DRUGOTHER and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and DRUGOTHER (coadministration of DRUG1 and DRUGOTHER may interfere with the efficacy of the DRUGOTHER).",melatonin,melatonin,False,Neg,0,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,13,-1
532,20013,20013,20546,20546,"Concomitant administration of low-dose DRUGOTHER with DRUG1 may result in an increased rate of GI ulceration or other complications, compared to use of DRUG1 alone. ",MOBIC,MOBIC,False,Neg,0,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,6,-1
533,20025,20025,20558,20558,"DRUG1: Clinical studies, as well as post-marketing observations, have shown that DRUGOTHER can reduce the natriuretic effect of DRUG2 and DRUGOTHER in some patients. ",Furosemide,furosemide,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,0,18
534,20026,20026,20559,20559,Studies with DRUG1 agents and DRUG2 have not demonstrated a reduction in natriuretic effect. ,furosemide,meloxicam,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,2,5
535,20027,20027,20560,20560,DRUG1: single and multiple dose pharmacodynamics and pharmacokinetics are not affected by multiple doses of DRUG2. ,Furosemide,meloxicam,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,0,15
536,20028,20028,20561,20561,"Nevertheless, during concomitant therapy with DRUG1 and DRUG2, patients should be observed closely for signs of declining renal function, as well as to assure diuretic efficacy. ",furosemide,MOBIC,True,advise,1,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,5,7
537,20131,20131,20664,20664,"DRUGOTHER may also affect the effects of other drugs, which include some DRUGOTHER, DRUGOTHER, certain heart medicines, birth control pills, DRUGOTHER, DRUG1 and DRUG2 Please note that DRUGOTHER may interact with other drugs that are not listed here.",furosemide,theophylline,False,Neg,0,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,CN1C2=C(C(=O)N(C1=O)C)NC=N2,21,23
538,20143,20143,20689,20689,DRUG1: DRUG1 clearance may decrease when hyperthyroid patients on a stable DRUGOTHER regimen become euthyroid; ,Theophylline,Theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,0,-1
539,20144,20144,20690,20690,DRUG1: DRUG1 clearance may decrease when hyperthyroid patients on a stable DRUG2 regimen become euthyroid; ,Theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,0,11
540,20145,20145,20691,20691,DRUG1: DRUG1 clearance may decrease when hyperthyroid patients on a stable DRUG2 regimen become euthyroid; ,Theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,0,11
541,20251,20251,20797,20797,"Less potent inhibitors include DRUG1, DRUG2, DRUGOTHER, grapefruit juice, DRUGOTHER, DRUGOTHER, DRUGOTHER, and DRUGOTHER. ",saquinavir,nefazodone,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,4,5
542,20272,20272,20818,20818,Caution should be exercised when DRUG1    (DRUG2) is used concurrently with other DRUGOTHER or DRUGOTHER.,Methergine,methylergonovine maleate,False,Neg,0,CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C,CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C.C(=C\C(=O)O)\C(=O)O,5,9
543,20606,20606,21163,21163,Concurrent use of DRUGOTHER    and DRUG1 may lead to increased plasma DRUG1 levels. ,theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,8,-1
544,20617,20617,21174,21174,"This increase was observed at the first test point which was the second day after starting DRUGOTHER   . DRUG1 plasma levels returned to pre-DRUGOTHER    values within 48 hours after discontinuing DRUGOTHER   . If DRUGOTHER and DRUG2 are to be used concurrently, DRUG2 blood levels should be monitored, particularly when the DRUGOTHER    dose is changed. ",Theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,20,42
545,20618,20618,21175,21175,"This increase was observed at the first test point which was the second day after starting DRUGOTHER   . DRUG1 plasma levels returned to pre-DRUGOTHER    values within 48 hours after discontinuing DRUGOTHER   . If DRUGOTHER and DRUG2 are to be used concurrently, DRUG2 blood levels should be monitored, particularly when the DRUGOTHER    dose is changed. ",Theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,20,42
546,20632,20632,21189,21189,"This increase was observed at the first test point which was the second day after starting DRUGOTHER   . DRUGOTHER plasma levels returned to pre-DRUGOTHER    values within 48 hours after discontinuing DRUGOTHER   . If DRUGOTHER and DRUG1 are to be used concurrently, DRUG1 blood levels should be monitored, particularly when the DRUGOTHER    dose is changed. ",theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,42,-1
547,20674,20674,21236,21236,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between DRUGOTHER and DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, and DRUGOTHER. ",sirolimus,ritonavir,False,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,26,29
548,20698,20698,21260,21260,DRUG1 AUC was increased by 21% with no effect on Cmax in the presence of steady-state DRUGOTHER compared with DRUG2 alone. ,Sirolimus,sirolimus,False,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,0,19
549,20705,20705,21267,21267,Patients receiving DRUG1 or DRUGOTHER in combination with DRUGOTHER should be monitored for DRUG1 or DRUGOTHER toxicity and DRUG1 or DRUGOTHER dosage should be reduced if necessary. ,sirolimus,sirolimus,False,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,2,-1
550,20707,20707,21269,21269,Patients receiving DRUG1 or DRUGOTHER in combination with DRUGOTHER should be monitored for DRUG1 or DRUGOTHER toxicity and DRUG1 or DRUGOTHER dosage should be reduced if necessary. ,sirolimus,sirolimus,False,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,2,-1
551,20719,20719,21281,21281,Patients receiving DRUG1 or DRUGOTHER in combination with DRUGOTHER should be monitored for DRUG1 or DRUGOTHER toxicity and DRUG1 or DRUGOTHER dosage should be reduced if necessary. ,sirolimus,sirolimus,False,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,2,-1
552,20762,20762,21324,21324,"The sedative effect of DRUGOTHER is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly DRUGOTHER (eg, DRUGOTHER, DRUG1 and DRUG2), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER and DRUGOTHER. ",meperidine,fentanyl,False,Neg,0,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,22,24
553,20927,20927,21495,21495,"Interaction with DRUG1: Although DRUGOTHER does not itself cause orthostatic hypotension, its administration to patients already receiving DRUG2 can result in profound orthostatic effects. ",Guanethidine,guanethidine,False,Neg,0,C1CCCN(CCC1)CCN=C(N)N,C1CCCN(CCC1)CCN=C(N)N,2,17
554,21236,21236,21817,21817,"DRUG1, DRUGOTHER, and DRUGOTHER: In patients treated with potent inducers of CYP3A4 (i.e., DRUG2, DRUGOTHER, and DRUGOTHER), the clearance of DRUGOTHER was significantly increased and DRUGOTHER blood concentrations were decreased. ",Phenytoin,phenytoin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,0,13
555,21298,21298,21880,21880,"DRUGOTHER: In a multiple-dose study in 30 normal weight subjects, coadministration of DRUG1 and 40 grams of DRUGOTHER (e.g., approximately 3 glasses of wine) did not result in alteration of DRUGOTHER pharmacokinetics, DRUG2 pharmacodynamics (fecal fat excretion), or systemic exposure to DRUG2. ",XENICAL,orlistat,False,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,12,32
556,21299,21299,21881,21881,"DRUGOTHER: In a multiple-dose study in 30 normal weight subjects, coadministration of DRUG1 and 40 grams of DRUGOTHER (e.g., approximately 3 glasses of wine) did not result in alteration of DRUGOTHER pharmacokinetics, DRUG2 pharmacodynamics (fecal fat excretion), or systemic exposure to DRUG2. ",XENICAL,orlistat,False,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,12,32
557,21305,21305,21887,21887,"DRUGOTHER: In a multiple-dose study in 30 normal weight subjects, coadministration of DRUGOTHER and 40 grams of DRUGOTHER (e.g., approximately 3 glasses of wine) did not result in alteration of DRUGOTHER pharmacokinetics, DRUG1 pharmacodynamics (fecal fat excretion), or systemic exposure to DRUG1. ",orlistat,orlistat,False,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,32,-1
558,21313,21313,21895,21895,DRUGOTHER: Preliminary data from a DRUG1 and DRUGOTHER drug interaction study indicate a reduction in DRUGOTHER plasma levels when DRUG1 was coadministered with DRUGOTHER. ,XENICAL,XENICAL,False,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,5,-1
559,21324,21324,21906,21906,"DRUGOTHER: In 12 normal-weight subjects receiving DRUG1 120 mg three times a day for 6 days, DRUG1 did not alter the pharmacokinetics of a single dose of DRUGOTHER. ",XENICAL,XENICAL,False,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,6,-1
560,21336,21336,21920,21920,"DRUGOTHER: In 12 normal-weight subjects receiving DRUG1 80 mg three times a day for 5 days, DRUG1 did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of DRUGOTHER. ",orlistat,orlistat,False,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,6,-1
561,21342,21342,21926,21926,"DRUGOTHER (extended-release tablets): In 17 normal-weight subjects receiving DRUG1 120 mg three times a day for 6 days, DRUG1 did not alter the bioavailability of DRUGOTHER (extended-release tablets). ",XENICAL,XENICAL,False,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,8,-1
562,21346,21346,21930,21930,"DRUG1: In 12 normal-weight subjects receiving DRUG2 120 mg three times a day for 7 days, DRUG2 did not alter the pharmacokinetics of a single 300-mg dose of DRUGOTHER. ",Phenytoin,XENICAL,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,0,6
563,21347,21347,21931,21931,"DRUG1: In 12 normal-weight subjects receiving DRUG2 120 mg three times a day for 7 days, DRUG2 did not alter the pharmacokinetics of a single 300-mg dose of DRUGOTHER. ",Phenytoin,XENICAL,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,0,6
564,21348,21348,21932,21932,"DRUG1: In 12 normal-weight subjects receiving DRUGOTHER 120 mg three times a day for 7 days, DRUGOTHER did not alter the pharmacokinetics of a single 300-mg dose of DRUG2. ",Phenytoin,phenytoin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,0,28
565,21349,21349,21933,21933,"DRUGOTHER: In 12 normal-weight subjects receiving DRUG1 120 mg three times a day for 7 days, DRUG1 did not alter the pharmacokinetics of a single 300-mg dose of DRUGOTHER. ",XENICAL,XENICAL,False,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,6,-1
566,21350,21350,21934,21934,"DRUGOTHER: In 12 normal-weight subjects receiving DRUG1 120 mg three times a day for 7 days, DRUG1 did not alter the pharmacokinetics of a single 300-mg dose of DRUG2. ",XENICAL,phenytoin,False,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,6,28
567,21351,21351,21935,21935,"DRUGOTHER: In 12 normal-weight subjects receiving DRUG1 120 mg three times a day for 7 days, DRUG1 did not alter the pharmacokinetics of a single 300-mg dose of DRUG2. ",XENICAL,phenytoin,False,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,6,28
568,21352,21352,21936,21936,"DRUG1: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving DRUG2 120 mg three times a day for 6 days, DRUG2 did not affect the pharmacokinetics of DRUGOTHER. ",Pravastatin,XENICAL,False,Neg,0,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,0,13
569,21353,21353,21937,21937,"DRUG1: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving DRUG2 120 mg three times a day for 6 days, DRUG2 did not affect the pharmacokinetics of DRUGOTHER. ",Pravastatin,XENICAL,False,Neg,0,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,0,13
570,21354,21354,21938,21938,"DRUG1: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving DRUGOTHER 120 mg three times a day for 6 days, DRUGOTHER did not affect the pharmacokinetics of DRUG2. ",Pravastatin,pravastatin,False,Neg,0,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,0,30
571,21355,21355,21939,21939,"DRUGOTHER: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving DRUG1 120 mg three times a day for 6 days, DRUG1 did not affect the pharmacokinetics of DRUGOTHER. ",XENICAL,XENICAL,False,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,13,-1
572,21356,21356,21940,21940,"DRUGOTHER: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving DRUG1 120 mg three times a day for 6 days, DRUG1 did not affect the pharmacokinetics of DRUG2. ",XENICAL,pravastatin,False,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,13,30
573,21357,21357,21941,21941,"DRUGOTHER: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving DRUG1 120 mg three times a day for 6 days, DRUG1 did not affect the pharmacokinetics of DRUG2. ",XENICAL,pravastatin,False,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,13,30
574,21361,21361,21945,21945,"Although undercarboxylated osteocalcin, a marker of vitamin K nutritional status, was unaltered with DRUG1 administration, vitamin K levels tended to decline in subjects taking DRUG1. ",XENICAL,XENICAL,False,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,13,-1
575,21366,21366,21950,21950,"Therefore, as DRUGOTHER absorption may be decreased with DRUG1, patients on chronic stable doses of DRUGOTHER who are prescribed DRUG1 should be monitored closely for changes in coagulation parameters.",XENICAL,XENICAL,False,Neg,0,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,8,-1
576,21462,21462,22046,22046,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",theophylline,caffeine,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,22,25
577,21477,21477,22061,22061,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",theophylline,phenytoin,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,22,45
578,21540,21540,22124,22124,"Based on studies evaluating possible interactions of DRUGOTHER with other drugs, no dosage adjustment is needed with concomitant use of the following: DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER (and its active metabolite, desmethylDRUGOTHER), DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, an oral DRUGOTHER (DRUGOTHER/DRUGOTHER), DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, or DRUGOTHER. ",caffeine,phenytoin,False,Neg,0,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,25,45
579,21847,21847,22434,22434,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER or DRUGOTHER. ",nefazodone,ritonavir,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,58,60
580,21848,21848,22435,22435,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER or DRUGOTHER. ",nefazodone,saquinavir,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,58,61
581,21849,21849,22436,22436,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2 or DRUGOTHER. ",nefazodone,telithromycin,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,58,62
582,21855,21855,22442,22442,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER or DRUGOTHER. ",ritonavir,saquinavir,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,60,61
583,21856,21856,22443,22443,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2 or DRUGOTHER. ",ritonavir,telithromycin,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,60,62
584,21858,21858,22445,22445,"A multiple dose drug-drug interaction study demonstrated that DRUGOTHER approximately doubled DRUGOTHER AUC0-   . Since DRUGOTHER is partially metabolized by CYP3A and DRUGOTHER le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing DRUGOTHER with DRUGOTHER and other strong P450 3A inhibitors including DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2 or DRUGOTHER. ",saquinavir,telithromycin,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,61,62
585,21876,21876,22471,22471,Concomitant administration of DRUG1 and DRUG2-containing drugs leads to increased DRUG2 levels and DRUG2 toxicity in some individuals. ,TRENTAL,theophylline,True,mechanism,4,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,CN1C2=C(C(=O)N(C1=O)C)NC=N2,3,5
586,21877,21877,22472,22472,Concomitant administration of DRUG1 and DRUG2-containing drugs leads to increased DRUG2 levels and DRUG2 toxicity in some individuals. ,TRENTAL,theophylline,False,Neg,0,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,CN1C2=C(C(=O)N(C1=O)C)NC=N2,3,5
587,21878,21878,22473,22473,Concomitant administration of DRUG1 and DRUG2-containing drugs leads to increased DRUG2 levels and DRUG2 toxicity in some individuals. ,TRENTAL,theophylline,False,Neg,0,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,CN1C2=C(C(=O)N(C1=O)C)NC=N2,3,5
588,21879,21879,22474,22474,Concomitant administration of DRUGOTHER and DRUG1-containing drugs leads to increased DRUG1 levels and DRUG1 toxicity in some individuals. ,theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,5,-1
589,21880,21880,22475,22475,Concomitant administration of DRUGOTHER and DRUG1-containing drugs leads to increased DRUG1 levels and DRUG1 toxicity in some individuals. ,theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,5,-1
590,21881,21881,22476,22476,Concomitant administration of DRUGOTHER and DRUG1-containing drugs leads to increased DRUG1 levels and DRUG1 toxicity in some individuals. ,theophylline,theophylline,False,Neg,0,CN1C2=C(C(=O)N(C1=O)C)NC=N2,CN1C2=C(C(=O)N(C1=O)C)NC=N2,5,-1
591,21895,21895,22490,22490,"Because DRUG1 is approximately 90% bound to plasma proteins, caution should be exercised if DRUG1 is coadministered with other drugs known to affect protein binding.",pergolide mesylate,pergolide mesylate,False,Neg,0,CCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC.CS(=O)(=O)O,CCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC.CS(=O)(=O)O,1,-1
592,22010,22010,22606,22606,"DRUG1 has been used with a variety of DRUGOTHER, including DRUG2, DRUGOTHER, and DRUGOTHER without unexpected adverse interactions. ",Pindolol,hydrochlorothiazide,False,Neg,0,CC(C)NCC(COC1=CC=CC2=C1C=CN2)O,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,0,10
593,22011,22011,22607,22607,"DRUG1 has been used with a variety of DRUGOTHER, including DRUGOTHER, DRUG2, and DRUGOTHER without unexpected adverse interactions. ",Pindolol,hydralazine,False,Neg,0,CC(C)NCC(COC1=CC=CC2=C1C=CN2)O,C1=CC=C2C(=C1)C=NN=C2NN,0,11
594,22012,22012,22608,22608,"DRUG1 has been used with a variety of DRUGOTHER, including DRUGOTHER, DRUGOTHER, and DRUG2 without unexpected adverse interactions. ",Pindolol,guanethidine,False,Neg,0,CC(C)NCC(COC1=CC=CC2=C1C=CN2)O,C1CCCN(CCC1)CCN=C(N)N,0,13
595,22016,22016,22612,22612,"DRUGOTHER has been used with a variety of DRUGOTHER, including DRUG1, DRUG2, and DRUGOTHER without unexpected adverse interactions. ",hydrochlorothiazide,hydralazine,False,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,C1=CC=C2C(=C1)C=NN=C2NN,10,11
596,22017,22017,22613,22613,"DRUGOTHER has been used with a variety of DRUGOTHER, including DRUG1, DRUGOTHER, and DRUG2 without unexpected adverse interactions. ",hydrochlorothiazide,guanethidine,False,Neg,0,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,C1CCCN(CCC1)CCN=C(N)N,10,13
597,22018,22018,22614,22614,"DRUGOTHER has been used with a variety of DRUGOTHER, including DRUGOTHER, DRUG1, and DRUG2 without unexpected adverse interactions. ",hydralazine,guanethidine,False,Neg,0,C1=CC=C2C(=C1)C=NN=C2NN,C1CCCN(CCC1)CCN=C(N)N,11,13
598,22019,22019,22615,22615,DRUG1 has been shown to increase serum DRUG2 levels when both drugs are co-administered. ,Pindolol,thioridazine,True,mechanism,4,CC(C)NCC(COC1=CC=CC2=C1C=CN2)O,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,0,7
599,22196,22196,22796,22796,DRUG1: Concurrent use of DRUGOTHER and DRUG2 may result in a reduction of the antibacterial action of the DRUGOTHER. ,Sulfonamides,sulfonamides,False,Neg,0,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2,0,6
600,22222,22222,22822,22822,"The induction dose requirements of DRUGOTHER Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with DRUGOTHER (eg, DRUGOTHER, DRUG1, and DRUG2, etc.) ",meperidine,fentanyl,False,Neg,0,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,23,25
601,22311,22311,22916,22916,Interactions for DRUG1 (DRUG2):  DRUGOTHER - impairs the intestinal absorption of DRUGOTHER,Vitamin B2,Riboflavin,False,Neg,0,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](CO)O)O)O,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](CO)O)O)O,2,3
602,22313,22313,22918,22918,Interactions for DRUG1 (DRUGOTHER):  DRUGOTHER - impairs the intestinal absorption of DRUG2,Vitamin B2,riboflavin,False,Neg,0,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](CO)O)O)O,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](CO)O)O)O,2,12
603,22315,22315,22920,22920,Interactions for DRUGOTHER (DRUG1):  DRUGOTHER - impairs the intestinal absorption of DRUG2,Riboflavin,riboflavin,False,Neg,0,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](CO)O)O)O,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](CO)O)O)O,3,12
604,22511,22511,23143,23143,"It may also interact with DRUG1 (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUG2 (decreased hepatic clearance of DRUG2).",thiazides,phenytoin,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,5,25
605,22512,22512,23144,23144,"It may also interact with DRUG1 (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUG2 (decreased hepatic clearance of DRUG2).",thiazides,phenytoin,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,5,25
606,22527,22527,23159,23159,"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUG1 (decreased hepatic clearance of DRUG1).",phenytoin,phenytoin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,25,-1
607,22547,22547,23179,23179,"It may also interact with DRUG1 (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUG2 (decreased hepatic clearance of DRUG2).",thiazides,phenytoin,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,5,25
608,22548,22548,23180,23180,"It may also interact with DRUG1 (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUG2 (decreased hepatic clearance of DRUG2).",thiazides,phenytoin,False,Neg,0,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,5,25
609,22563,22563,23195,23195,"It may also interact with DRUGOTHER (increased thrombocytopenia), DRUGOTHER (increased nephrotoxicity), DRUGOTHER (increased hypoglycemic response), DRUGOTHER (increased anticoagulant effect), DRUGOTHER (decreased renal excretion of DRUGOTHER), DRUG1 (decreased hepatic clearance of DRUG1).",phenytoin,phenytoin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,25,-1
610,22569,22569,23201,23201,"Because there is a theoretical basis that these effects may be additive, use of DRUGOTHER-containing or DRUGOTHER (like dihydroDRUGOTHER or DRUG1) and DRUG2 within 24 hours of each other should be avoided. ",methysergide,sumatriptan,True,advise,1,CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CN(C4=CC=CC(=C34)C2=C1)C)C,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,20,22
611,22574,22574,23206,23206,"Therefore, the use of DRUG1 tablets in patients receiving DRUGOTHER is contraindicated . DRUGOTHER (DRUGOTHER) (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with DRUG2. ",sumatriptan succinate,sumatriptan,False,Neg,0,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C.C(CC(=O)O)C(=O)O,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,4,33
612,22637,22637,23269,23269,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",nefazodone,ritonavir,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,16,18
613,22638,22638,23270,23270,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",nefazodone,saquinavir,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,16,19
614,22639,22639,23271,23271,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG2, DRUGOTHER) may increases DRUGOTHER concentrations. ",nefazodone,telithromycin,False,Neg,0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,16,20
615,22645,22645,23277,23277,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER, DRUGOTHER) may increases DRUGOTHER concentrations. ",ritonavir,saquinavir,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,18,19
616,22646,22646,23278,23278,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUGOTHER, DRUG2, DRUGOTHER) may increases DRUGOTHER concentrations. ",ritonavir,telithromycin,False,Neg,0,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,18,20
617,22648,22648,23280,23280,"Co-administration of DRUGOTHER with strong inhibitors of the CYP3A4 family (e.g., DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUGOTHER, DRUG1, DRUG2, DRUGOTHER) may increases DRUGOTHER concentrations. ",saquinavir,telithromycin,False,Neg,0,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,19,20
618,22956,22956,23621,23621,"DRUGOTHER, given at a common clinical dosage, increased the DRUG1 half-life by 51% and decreased the DRUG1 metabolic clearance rate by 30%. ",phenytoin,phenytoin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,9,-1
619,23038,23038,23713,23713,"In 1984, Drs Rimmer and Richens at the University of Wales reported that administering DRUGOTHER with DRUG1 lowered the serum DRUG1 concentration in patients with treatment-resistant epilepsy. ",phenytoin,phenytoin,False,Neg,0,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,16,-1
620,23042,23042,23718,23718,"Weekly intramuscular DRUG1 injections (0.2-0.5 mg/kg body weight), in combination with daily administration of DRUGOTHER or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (DRUG1/DRUGOTHER versus DRUG1/vehicle). ","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",False,Neg,0,CN1CCC(=CC1)C2=CC=CC=C2,CN1CCC(=CC1)C2=CC=CC=C2,2,-1
621,23043,23043,23719,23719,"Weekly intramuscular DRUG1 injections (0.2-0.5 mg/kg body weight), in combination with daily administration of DRUGOTHER or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (DRUG1/DRUGOTHER versus DRUG1/vehicle). ","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",False,Neg,0,CN1CCC(=CC1)C2=CC=CC=C2,CN1CCC(=CC1)C2=CC=CC=C2,2,-1
622,23044,23044,23720,23720,"Weekly intramuscular DRUG1 injections (0.2-0.5 mg/kg body weight), in combination with daily administration of DRUGOTHER or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (DRUG1/DRUGOTHER versus DRUG1/vehicle). ","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",False,Neg,0,CN1CCC(=CC1)C2=CC=CC=C2,CN1CCC(=CC1)C2=CC=CC=C2,2,-1
623,23045,23045,23721,23721,"After 21 weeks of DRUG1 treatment, all DRUG1/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the DRUG1/DRUGOTHER-treated monkeys were significantly affected. ","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",False,Neg,0,CN1CCC(=CC1)C2=CC=CC=C2,CN1CCC(=CC1)C2=CC=CC=C2,4,-1
624,23046,23046,23722,23722,"After 21 weeks of DRUG1 treatment, all DRUG1/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the DRUG1/DRUGOTHER-treated monkeys were significantly affected. ","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",False,Neg,0,CN1CCC(=CC1)C2=CC=CC=C2,CN1CCC(=CC1)C2=CC=CC=C2,4,-1
625,23047,23047,23723,23723,"After 21 weeks of DRUG1 treatment, all DRUG1/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the DRUG1/DRUGOTHER-treated monkeys were significantly affected. ","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",False,Neg,0,CN1CCC(=CC1)C2=CC=CC=C2,CN1CCC(=CC1)C2=CC=CC=C2,4,-1
626,23048,23048,23724,23724,"These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in DRUG1/DRUGOTHER-treated animals than in DRUG1/vehicle-treated monkeys. ","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",False,Neg,0,CN1CCC(=CC1)C2=CC=CC=C2,CN1CCC(=CC1)C2=CC=CC=C2,43,-1
627,23049,23049,23725,23725,"In DRUG1/vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in DRUG1/DRUGOTHER-treated monkeys. ","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",False,Neg,0,CN1CCC(=CC1)C2=CC=CC=C2,CN1CCC(=CC1)C2=CC=CC=C2,1,-1
628,23052,23052,23729,23729,"Effect of DRUGOTHER-mediated CYP3A4 inhibition on clinical pharmacokinetics of DRUG1 (DRUG2), an orally active DRUGOTHER.
",panobinostat,LBH589,False,Neg,0,CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO,CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO,9,10
629,23056,23056,23735,23735,Co-administration of DRUG1 with CYP3A inhibitors is feasible as the observed increase in DRUG1 PK parameters was not considered clinically relevant. ,panobinostat,panobinostat,False,Neg,0,CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO,CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO,2,-1
630,23057,23057,23736,23736,"Considering the variability in exposure following enzyme inhibition and the fact that chronic dosing of DRUG1 was not studied with CYP3A inhibitors, close monitoring of DRUG1-related adverse events is necessary.",panobinostat,panobinostat,False,Neg,0,CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO,CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO,15,-1
631,23227,23227,23927,23927,"and/or DRUGOTHER DRUG1 (100 mg/kg, p. o.), as well as that of neurotoxin DRUGOTHER (DRUG2) (4 x 20 mg/kg, i. p.) ",doxycycline,MPTP,False,Neg,0,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CN1CCC(=CC1)C2=CC=CC=C2,2,14
632,23233,23233,23934,23934,"Treatment of HEY xenograft-bearing mice with DRUG1 plus DRUGOTHER inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, DRUG1 + DRUGOTHER vs DRUGOTHER: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",dasatinib,dasatinib,False,Neg,0,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,6,-1
633,23250,23250,23951,23951,"Phase I trial of DRUGOTHER and DRUG1 in patients with relapsed multiple myeloma: evidence for DRUGOTHER-DRUG1 interaction via P-glycoprotein.
",CCI-779,CCI-779,False,Neg,0,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OC(=O)C(C)(CO)CO)C)/C)O)OC)C)C)/C)OC,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OC(=O)C(C)(CO)CO)C)/C)O)OC)C)C)/C)OC,6,-1
